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ABSTRACT
Exploration of the Low-Molecular Weight Proteome of Tissue and Serum,
with Applications to Disease Biomarker Discovery
Meihwa Tanielle Alvarez
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
The low-molecular weight proteome is of great interest due to the vast number of smaller
proteins and peptides present within it, some of which are likely to be disease-related and may
provide insights into disease mechanisms or even prediction and diagnosis. Serum is often the
most preferred specimen for disease prediction or diagnosis, as it can be obtained less-invasively
and its collection is fairly routine in a clinical setting. Although serum samples are one of the
most preferred specimens for disease studies, additional disease information may also be
obtained using other specimens, such as tissue. The study of tissue specimens can be extremely
valuable in disease studies as it likely contains the highest concentration of potential markers for
tissue related diseases. Therefore, despite the difficulty of sample collection, as compared to
serum specimens, tissue specimens can be invaluable in studying tissue-related diseases. Tissue
proteomics approaches for studying the low-molecular weight proteome of tissue have been
infrequently described in the literature, which suggests the need to develop new methods or
improve upon current proteomics approaches to better study this subset of the proteome in tissue.
In this dissertation, I first report on a low-molecular weight tissue proteomics approach that we
have developed based on a previously reported serum approach. As reported here, we conclude
that this tissue proteomics approach cannot only distinguish the low-molecular weight proteome
of different tissue types, but it also appears to be within the reproducibility range of other
currently used proteomic approaches. Additionally, we also report on the use of a serum
proteomics approach for biomarker discovery and identification in preeclampsia and
endometriosis. These studies reveal many candidate biomarkers for preeclampsia prediction and
endometriosis diagnosis. In the preeclampsia study we discovered several candidate biomarkers
early in pregnancies (12-14 weeks gestation) that were able to predict preeclampsia later in
pregnancy with statistical significance. In the endometriosis study, several candidate biomarkers
were discovered that were statistically significant in diagnosing endometriosis. Further, for both
preeclampsia and endometriosis, combinations of 3 or 4 biomarkers yielded an improved
sensitivity and specificity in disease prediction and diagnosis with combined area under the
curves of greater than 0.8. Thus, the low-molecular weight proteome of both tissue and serum
could potentially provide important information regarding disease physiology, prediction, and
diagnosis that may supplement our current understanding of these processes.

Keywords: low-molecular weight proteome, serum proteomics, tissue proteomics, endometriosis,
preeclampsia
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1. Chapter 1 - Introduction
Proteomics
The proteome was first defined in 1995 and was described as "the total protein content of
a genome" (Wilkins 1996). Hence, proteomics can de defined as the study of the total protein
content of the genome. Proteomics has been of great interest in part due to the fact that proteins
are considered to contain a greater information load than genomic material, because of various
regulatory co- or post-translational modifications that commonly occur in proteins (Kohn 2007).
Additionally, proteomics studies are also attractive because proteins interact with other classes of
molecules, including other proteins, which can provide additional information regarding
molecular interactions in organisms (Gstaiger 2009).
The field of proteomics has grown in the recent years due to the acceleration and
completion of the human genome project (Veenstra 2005, Ray 2011). The mapping of the human
genome as well as other organisms has led to dramatic growth in the proteomics field,
particularly in research associated with disease biomarker discoveries (Ray 2011). It is believed
that the protein domain is likely to be the most affected in disease, therapeutic response, or
recovery, which makes it a prime target for disease studies (Rifai 2006). In biomarker discovery
studies, typically, amino acid sequences or protein peptide fingerprints of specific proteins or
peptides of interest are compared to databases originating from genomic sequences of various
organisms in order to determine the identities of peptides or proteins of interest (Chiou 2011). As
a result of being able to determine peptide or protein identities, there has been significant
progress in biomedical research of disease pathogenesis, drug targets, as well as biomarker
discovery for early diagnosis of various prominent diseases (Hanash 2003,Zhan 2010).
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Despite major progress in proteomics studies, there are various challenges associated
with these studies, which are not found in genomic studies. One challenge is the complexity of
the entire proteome, consisting of splice variants as well as various post-translationally modified
versions of the proteins/peptides (Han 2008). Thus the complex proteome consists of proteins
and peptides with largely varying sizes and chemistries that may pose a challenge in separation
of these complex mixtures. Another aspect that contributes to its complexity is the highly
variable amounts of different proteins or peptides, which may pose an issue when attempting to
study lower abundance proteins without visible carryover interferences from higher abundance
species.
In the past, proteomic studies almost exclusively involved the use of 2D gel
electrophoresis (2DE), which separates a protein mixture based on molecular size and isoelectric
point (pI). In this approach, researchers compare spot patterns between specimens from diseased
patients and non-diseased controls to visualize differences in protein expressions that may be
disease-related (Kohn 2007, Li 2002). Spots on the gel that appear to be quantitatively different
across comparison groups are subjected to trypsin digestion followed by mass spectrometry
analysis, typically with the use of matrix-assisted laser desorption ionization mass spectrometry
(MALDI-MS) (Chiou 2011, Iwadate 2008).
This approach is not only relatively simple and can be done in a fairly short time, but it
has the ability to resolve more than 1000 proteins (Chiou 2011). However, the 2DE approach
poses significant challenges when studying lower molecular weight (MW) proteins, proteins with
pI values of less than 4 or greater than 9, proteins that comigrate in the same spots, less abundant
proteins (Maurya 2007), proteins much larger than the detection limit of 2DE, or complex
mixtures consisting of bound proteins (Chiou 2011). Another limitation of 2DE for biomarker
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discovery is the low throughput nature of this technique and that it requires a large amount of
clinical specimen due to its low sensitivity compared to mass spectrometry based techniques
(Kohn 2007). To overcome some of the shortcomings of 2DE, more and more research groups
are utilizing liquid chromatography-mass spectrometry (LC-MS) based approaches for
proteomics due to the higher sensitivity and reproducibility of such approaches (Rifai 2006).
Furthermore, rapid and ongoing advancements in mass spectrometry-based techniques have
essentially led to the replacement of 2DE in proteomics studies (Walther 2010).

Mass Spectrometry as a Tool for Biomarker Discovery
Mass spectrometry (MS) can be an effective tool in disease studies such as biomarker
discovery, particularly due to its ability to test many samples in one day while utilizing smaller
amounts of specimen compared to 2DE (Kohn 2007). Briefly, in one approach to MS
experiments, proteins or peptides of interest are acidified, ionized and conveyed into the gas
phase, where the exact MW of the species is measured and reported as a mass to charge (m/z)
ratio by determining its trajectory in an electric field (Han 2008, Walther 2010). In other MS
based experiments, an initial liquid chromatography (LC) separation is often coupled to the MS.
This coupling allows for the separation of thousands of proteins, which is particularly useful
when dealing with complex biological samples such as tissue, serum, plasma, or urine (Blonder
2011).
The two types of soft ionization methods used in biological MS are matrix assisted laser
desorption ionization (MALDI) and electrospray ionization (ESI), which have allowed for the
non-destructive ionization of larger proteins or peptides and their being put into the vapor phase.
Briefly, in MALDI experiments, the specimen, typically purified, is mixed with a solution of
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organic matrix molecule, spotted onto a plate, and allowed to dry. A laser is used to instantly
vaporize the matrix molecules and form ions and the ionized proteins/peptides are introduced in
the mass spectrometer. MALDI experiments have a high sensitivity and typically provide fairly
simple data, which is beneficial in the data analysis step (Davis 2007). This approach also has
high throughput, particularly for studies involving multiple specimens (Chiou 2011). However,
because proteins/ peptides are mainly only able to take on one positive charge in MALDI
experiments, there is a limitation in terms of the size of proteins that can be analyzed (Chiou
2011).
In ESI experiments, specimens in a liquid, often weakly acidic or basic, are pushed
through a fine gauge needle and are nebulized into very small droplets. As the droplets
evaporate, the concentration of acid or base ions in the droplet increases until it charges proteins
or peptides to form ions that become suspended in the vapor phase and are introduced to the
mass spectrometer. In ESI experiments, the results can be made highly reproducible (Chiou
2011). Additionally, the ionized proteins are able to take on multiple charges, allowing for the
analysis of larger molecules than what can be analyzed in MALDI experiments. However, the
mass spectra can be complex due to the presence of peaks representing multiply charged ions
(Chiou 2011).
Additionally, different mass analyzers have been used for biological mass spectrometry
research, including quadrupole, time of flight (TOF), ion trap, or fourier transform ion cyclotron
resonance (FTICR) instruments (Han 2008). However, the development of the orbitrap mass
analyzer in the early 2000s by Makarov (Makarov 2000, Hardman 2003) has opened up new
potentials in proteomics research due to the robustness, high sensitivity and high mass accuracy
leading to high mass spectrometric resolution of this instrument (Walther 2010). Taken together,
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mass spectrometry has become the preferred tool for biomarker discovery due to its resolution,
sensitivity, high mass accuracy, as well as rapid tandem MS (MS/MS) analyses, allowing for the
identification of many proteins of interest (Blonder 2011).

Mass Spectrometry for Determining Biomarker Identity
Once a protein or peptide is considered as a potential disease biomarker, it is important to
determine its chemical identity because it may provide information regarding the etiology,
progression, as well as possible treatments for the disease (Kohn 2007, Rifai 2006). There are
two main strategies that have been used in determining biomarker identity using mass
spectrometry, bottom-up and top-down proteomics. The concept behind bottom-up strategies is
that enzymatically digested peptides are used to infer the parent protein identity, whereas, topdown approaches rely on the analysis of intact, non-enzymatically digested peptides and proteins
(Han 2008). In both strategies, separation of peptides and proteins is an important element,
which is often achieved using methods such as reverse-phase, size-exclusion, or ion exchange
chromatography or using electrophoretic techniques such as isoelectric focusing, conducted
either on- or off-line with MS analysis (Han 2008).
One of the most commonly used bottom-up strategies in biomarker identification is
shotgun proteomics. Also known as the "break-then-sort" method, this approach involves LC
separation of trypsin-digested peptides which are then subjected to MS/MS followed by database
searches to determine the amino acid sequence or identity of the biomarkers of interest (Han
2008, Gstaiger 2009), as outlined in Figure 1.1.
Using this approach, researchers are able to perform automated sample analysis with high
throughput as well as sensitivity (Chiou 2011). Furthermore, using the shotgun approach,
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Figure 1.1 Bottom-up proteomics mass spectrometry strategy
Protein specimens are subjected to trypsin digestion. The digested peptides are separated via reversed-phase LC, and
introduced to the mass spectrometer through electrospray ionization (ESI). Mass to charge ratio of digested peptides
are measured, and the peptides are fragmented in the collision cell to obtain MS/MS spectra which are then
submitted for database search to determine the amino acid sequence and parent protein identity.
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researchers are able to identify as many proteins as possible from either disease case or nondiseased control specimens and compare the difference between the two separate specimen
groups (Blonder 2011). However, because of the many proteins being digested and analyzed, this
approach yields an increased complexity of the peptide mixture (Walther 2010). This complexity
increases the challenge in determining which proteins are most likely to be of clinical use
(Blonder 2011). In addition to increased complexity, the various peptides in the mixture are
present in a wide range of abundance, where the highly abundant ones are more readily observed
than the less abundant ones (Han 2008, Gstaiger 2009).
In top-down strategies (Figure 1.2), non-enzymatically digested proteins or peptides are
subjected to MS/MS analysis to examine the entire protein or peptide sequence, rather than
digested pieces of the protein (Chiou 2011, Han 2008). This approach can be problematic when
attempting to analyze large proteins (>50kD) due to several issues, including the increased
complexity of tertiary structure and noncovalent interactions in larger proteins as well as
limitations of certain fragmentation processes such as CID in fragmenting large proteins (Han
2008). However, when proteins or peptides of interest are of lower molecular weight, this
approach can be particularly useful.
Collision-induced dissociation (CID) is perhaps the most widely used MS/MS technique
in proteomics studies (Han 2008). This technique was first introduced in 1968 to obtain
structural information in MS/MS experiments (Haddon 1968). In order to perform CID
experiments, the mass spectrometer can have multiple mass analyzers, in which one mass
analyzer is used to obtain the mass spectrum of the entire sample, and another mass analyzer is
used to fragment the protein/ peptide of interest to determine its structure (Chiou 2011). In the
fragmentation step, inert gas such as nitrogen, argon, or helium is introduced at low pressure to
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Figure 1.2 Top-down proteomics mass spectrometry strategy.
Specimens consisting of intact proteins are separated via reversed-phase LC followed by ESI to introduce them into
the mass spectrometer. M/z values are measured for each protein in the mixture and a specific protein of interest is
introduced into the collision cell for CID fragmentation. MS/MS spectra are recorded and submitted to a database
search to determine amino acid sequence and identity of the protein of interest.
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the collision cell where they collide with the protein/peptide of interest (Walther 2010), typically
1 collision per protein/peptide on average. As a result, proteins or peptides are broken at the
peptide (C-N) bond, producing a series of b and y fragment ions (Han 2008). The b-ions
represent the amino terminal portion of the protein or peptide when the molecule is broken at the
peptide bond, whereas the y-ions represent the carboxy terminal portion of the protein or peptide
when broken at the peptide bond (Figure 1.3). The resulting MS/MS spectra can then be
submitted to proteomics database searches (such as Mascot or SEQUEST) to determine the
amino acid sequence and identity of the protein/peptide of interest.
In instances when database searches do not yield any matches, there are certain MS/MS
fragment data analysis steps that can be taken to perform de novo sequence determination.
Because CID experiments primarily give rise to b and y fragment ions, the resulting MS/MS
spectra basically represents a list of m/z ratios of the several fragments of the protein/peptide of
interest being fragmented at random peptide bonds throughout the length of the protein (Walther
2010). Therefore, in de novo sequencing, when starting from an N terminus (b ion series) or C
terminus (y ion series) peak, one can follow along the MS/MS spectra and record the m/z
differences between peaks to determine the amino acid sequence of the protein (Walther 2010).
It is to be expected that a single MS/MS spectrum may not necessarily provide good
coverage of the entire set of peaks representing a particular protein/ peptide sequence. However,
when multiple spectra are obtained using various collision energies, it is very likely that better
coverage can be obtained. As a general rule, increasing the collision energy (CE) will give rise to
smaller fragments (more peaks at the lower m/z end of the spectrum), and lower collision
energies will yield larger fragments (more peaks in the high end of the spectra) (Merrell 2009).
Thus, with this general rule in mind, when performing de novo sequencing, one can determine
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Figure 1.3 Chemical structure of a peptide with the b and y fragments labeled (taken from Steen 2004).
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which collision energies are needed in subsequent MS/MS runs to obtain a better fragmentation
coverage.
Figure 1.4 shows an example of this. The top panel represents a fragmentation spectrum
using CE 35 V. A decent fragmentation spectrum is obtained using this one CE. However, the
majority of fragments are located towards the higher end of the m/z range. The middle panel
represents a fragmentation spectra using CE 50 V. With this much higher CE, more fragments in
the middle and early m/z region are obtained. Combining multiple appropriate CEs (Figure 1.4
bottom panel) gave improved fragmentation coverage, including fragments in the early, middle
and later end of the m/z range.

Biomarker Overview
Biomarkers are defined as measurable entities that provide information regarding disease
risk, diagnosis, prognosis, stage, or treatment response and potentially predicting which
treatment will be effective, providing significant benefits for patient care (Kohn 2007, Rifai
2006). In comparing disease patients and non-disease controls, it is likely that differences in
certain marker levels are caused by the disease (Petricoin 2003). It has been proposed that such
differences may represent factors causing or participating in the disease or may be due to specific
cleavage processes, degradation, changes in expression, post translational modifications, or
proteolysis of certain molecules as a result of the disease process (Petricoin 2003). Other
possible reasons for such differences may include protein-protein interaction or complex
formations caused by the disease, which may cause changes in the proteome (Petricoin 2003).
Therefore, even though biomarkers for a given disease may appear unrelated to our current
knowledge of the disease, these biomarkers could still provide diagnostic information because
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Figure 1.4 Comparison of MS/MS spectrum with different collision energies (CE).
Top panel represents an MS/MS spectrum with CE 35. The middle panel represents an MS/MS spectrum with CE
50. The bottom panel represents a summed MS/MS spectrum of the two collision energies.
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the presence or absence of these markers may be the result of certain processes associated with
the disease (Petricoin 2003).
Biomarkers can be in the form of proteins, peptides, metabolites, and are preferably
sampled through non-invasive methods. Biomarkers that are of value are often readily obtainable
and provide good specificity as well as sensitivity (Kohn 2007, Tirumalai 2003). Biomarkers
may also have merit in providing information regarding disease etiology and mechanisms (Kohn
2007). Furthermore, in a clinical setting, biomarkers can not only provide means for diagnosis,
but also for the development of molecularly targeted therapeutic options as well as to assess for
the assessment of the patient's response to such therapeutic treatments (Rifai 2006).
In terms of patient care, biomarker discovery is also especially valuable for early
detection of disease or early risk assessment of future disease. One reason for this is that early
diagnosis allows for the administration of treatment options early in the disease stage, which in
turn translates into more effective treatment outcomes (Schilsky 2010). This also implies that
early diagnosis plays a role in reducing mortality rates. In many cases, despite advancements in
medicine, including drug discoveries, surgical methods, or other therapeutic approaches, disease
diagnosis is often too late for these remedies to positively influence patient survival (Veenstra
2005). As an example, a recent study reported that the overall five-year survival rate of cancer
has increased from 50% to 65% over the last 30 years, primarily due to improvements in early
cancer detection (Davis 2007). Additionally, early disease detection can also provide better
prognosis, which allows health care providers to better monitor the patients throughout the
course of treatment (Blonder 2011).
Various biological specimens have been used in the past for the purpose of biomarker
discovery. Some of these include blood (serum or plasma), tissue, proximal fluid, or urine. While
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there may be some overlap in information provided by each biological specimen, each specimen
is also likely to provide different types of information, depending on their proximity to disease
sites or other factors. Thus, there is some value in using a range of biological specimens for
diagnosis in order to obtain a good coverage of possible disease markers through all available
resources (Zhang 2012, Rifai 2006). A brief overview of the different types of biological
specimen will be outlined.

Proximal Fluid as a Medium for Biomarker Discovery
Proximal fluids are defined as biofluids that are located close to or are in direct contact
with the disease site (Rifai 2006). Some examples of proximal fluids include cerebrospinal fluid
or amniotic fluid. These fluids can be valuable for biomarker discovery because potential disease
biomarkers are likely to be enriched in fluids from diseased patients as opposed to non-diseased
controls, where the disease involves cerebral involvement or affects the fetus or placenta
respectively, due to its close proximity to the disease site (Rifai 2006). However, these types of
specimens are generally harder to obtain, and require more invasive procedures for sample
collection.

Urine as a Specimen for Biomarker Discovery
Urine can be of value, particularly when studying kidney-related diseases, as its proteome
is known to alter as a result of these types of diseases (Veenstra 2005). Urine can also be
interesting in studies of non-kidney-related diseases because it provides a snapshot of an
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individual's metabolism and may reveal various aspects of the disease such as disease state,
nutritional state, physiological state, genotype, environment or other factors (Atzori).
Urine is also often the specimen of choice due to the non-invasiveness of its sample
collection procedure and because it is routinely sampled at doctor's visits (Veenstra 2005, Atzori
2009). In fact, in early detection of disease, there is a continuous need for the discovery of highly
sensitive and specific biomarkers, particularly in biofluids such as urine or blood due to the noninvasive nature of these tests (Zhang 2012).

Tissue as a Medium for Biomarker Discovery
In tissue-related diseases, such as cancer, endometriosis, preeclampsia, and others, the
diseased-tissue would undoubtedly have the highest level of biomarkers of interest, and tissue
related biomarker concentrations are likely to diminish with distance from the diseased tissue
due to dilution into blood (Rifai 2006). Due to their proximity to the disease site, tissue
biomarkers are likely to provide more insights into the disease and potential diagnostic attributes
(Davis 2010). This makes tissue one of the most ideal samples for biomarker discovery in terms
of the visibility of biomarkers. Additionally, due to the probable high concentration of
biomarkers in those tissues that produce them, researchers are also able to perform various
mechanistic studies to determine which molecules are influenced by specific biomarkers of
interest (Blonder 2011).
The primary drawback in tissue proteomics is the difficulty in obtaining specimens,
which require more invasive approaches such as biopsies (Blonder 2011). It is impractical to
require biopsies during routine physical examinations for disease diagnosis (Blonder 2011). As a
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result, tissue marker studies are less common than studies using peripheral body fluids such as
serum or urine (Blonder 2011).

Blood as a Medium for Biomarker Discovery
Blood is another valuable specimen for biomarker discovery, as the sample collection
process does not involve extremely invasive procedures such as tissue biopsy. The blood
proteome is said to be the most complex human proteome because its components fluctuate in
response to the patient's physiological or pathological conditions (Ray 2011). Blood is also
known to have a high protein content, which is valuable for proteomics studies (Blonder 2011).
One logical reason for using blood as a specimen for biomarker discovery instead of
urine is the fact that blood is constantly being exposed to all organs as it travels through the
body, and is therefore likely to encounter and carry within it certain disease specific markers
such as proteins or other molecules originating from the diseased organs or tissues (Petricoin
2003, Kohn 2007). These biomarkers from tissue are secreted or leaked into the blood stream,
which allows for the observation of these markers in serum or plasma, albeit in lower
concentrations than their concentrations in diseased tissue (Ray 2011, Blonder 2011). These low
abundance circulating proteins may also originate from apoptotic or necrotic cells (Veenstra
2005). Therefore, blood is often considered to contain the largest version of the human proteome
compared to any other clinical sample, and as such, provides the richest source of potential
information regarding physiological or disease state (Anderson 2002). Blood volume is also far
more constant than urine output allowing concentration to be more useful.
Thus, when comparing blood specimens from diseased individuals and non-diseased
controls, disease-related alterations in the presence or abundance of secreted molecules can
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provide insights into disease mechanism, diagnosis, etc (Araujo 2008, Tirumalai 2003). In fact,
previous biomarker discovery studies have shown success in obtaining serum biomarkers for
various diseases such as cancer, autoimmune, infectious, as well as other diseases (Ray 2011).
Another benefit of using blood for biomarker discovery is to fulfill the ultimate goal of clinical
disease diagnosis, which is to develop a blood test that can be readily used in hospitals and
clinics due to the already established medical laboratory infrastructures and instrumentation for
blood testing (Rifai 2006). One drawback of using blood for biomarker discovery is the difficulty
in determining where exactly in the body any of these circulating biomarkers originated (Blonder
2011).
Two components of blood are often used for biomarker discovery research, serum and
plasma. While both types of blood samples may be valuable in studying secreted molecules that
enter into the blood as they are both considered related to each other, there is a distinction
between the two in how they are obtained. To obtain serum, blood specimens are allowed to
coagulate, and fibrin clots along with other coagulation factors as well as blood cells are
separated from the serum portion of the blood through centrifugation (Yu 2011, Ray 2011). To
obtain plasma, clotting is prevented through the addition of anticoagulants such as heparin or
ethylenediaminetetraacetic acid (EDTA) to the blood specimens prior to the removal of blood
cells (Yu 2011). Hence, plasma represents the liquid portion of blood (Ray 2011). Serum and
plasma are complex biological samples that not only contain a wide range of proteins but also
waste products, electrolytes, dissolved gases and water (Ray 2011).
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Biomarker Discovery Stages and Challenges
Technological advances in sample acquisition, processing, fractionation, preparation,
mass spectrometry, bioinformatics, as well as data analysis and interpretation have been an
advantage to the evolution of proteomics biomarker discovery (Kohn 2007). In general,
biomarker discovery involves multiple stages, including discovery, verification, as well as
validation and clinical trials (Chiou 2011), where validated markers are usually submitted for
further steps which may involve the development of non-MS based assays and optimization for
its use in clinical settings (Rifai 2006). These steps have been greatly improved over the years
due to more sophisticated instruments and better techniques. Therefore, it is reasonable to
conclude that validation of markers is perhaps just as important as the discovery of markers.
Many potential biomarkers for diseases such as cancer and others have been published in the
literature over the years, however, in many cases there appears to be an overemphasis on the
discovery of novel biomarkers and a lack of effort to validate the diagnostic capabilities of these
markers (Rifai 2006).
In the discovery step, although blood has been widely considered as a good specimen for
biomarker discovery due to the minimally invasive nature of its collection, low sample amount
requirement and high throughput of analysis, there are several challenges associated with its use
in proteomics marker discovery (Davis 2007). Some of the challenges include human or disease
variability, pre-analytical variables and dynamic range.

Human and Disease Variability Associated with Blood Proteomics
One of the major challenges in biomarker discovery is the presence of human or disease
variability (Rifai 2006). For instance, due to the complex nature of human pathophysiology, not
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all non-disease controls or not all disease patients may yield the same blood proteomic profile.
These variations could be due to a number of factors, including but not limited to dietary
considerations, gender, age, genetic factors, environment, medication (Ray 2011), or
comorbidities. This variability poses a challenge in terms of determining whether an observed
differentially expressed marker is due to human variation or whether it is an actual factor that can
provide clear distinction between disease cases and controls.
Likewise, within a disease itself, there may be variations in the proteomic profile
generated in each diseased individual. These variations could be indicative of the severity of the
disease, where individuals with a more advanced stage of the disease may have a different
proteomic profile than those who have a less advanced stage of the disease. Additionally, in the
case of multifactorial diseases such as preeclampsia or endometriosis, where the diseases likely
involve multiple mechanisms, there may also be biomarker pattern differences as a result of
which type of disease or which disease factor is present in the individual.

Pre-Analytical Challenges Associated with Blood Proteomics
The first challenge is associated with pre-analytical considerations, such as sample
collection, storage, and processing (Ray 2011). An example of this can be seen in the case of
serum, where despite the removal of background proteins through clotting and centrifugation,
there are still ongoing enzymatic activities that may affect the proteins in serum (Koomen 2005).
This emphasizes the significance of proper sample collection, storage, and processing.
Sample collection can potentially be a source of significant alterations, in which proteins
or peptides may be degraded when specimens aren't collected with proper care or precautions
(Chiou 2011). Improperly handled and collected specimens have been shown to assay affect
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sensitivity, selectivity as well as reproducibility of the study (Haleem 2007). Several researchers
have suggested that temperature and clotting duration can influence the results of a study (WestNielsen 2005). Therefore, in the sample collection stage of a study, it is important to establish
proper protocols regarding temperature and time, such as keeping the samples on ice and
designating a specific length of clotting time that is consistently used for all specimens within a
study set.
Another factor to be considered in sample collection is the possibility of adsorption of
serum proteins to the sides of the sample collection and storage tubes (Hsieh 2006). This can be
minimized by using specific tubes designed to minimize protein adsorption.
In terms of sample storage, specimens should be frozen and stored at low temperatures (80oC) to minimize the adverse effects of high temperatures on proteomic analysis. Additionally,
it is best to store specimens in small aliquots to avoid multiple freeze-thaw cycles that may
increase pre-analytical variability (Rai 2005).
In the sample processing step some aspects to consider include not only length of time
between collection and processing, but also whether or not to use protease inhibitors. In general,
previous studies have suggested the value of minimizing the time interval between sample
collection and processing to reduce likelihood of changes (degradation, cleavage, modifications)
to occur in the specimens (Davis 2007). Additionally, if protein degradation is a concern, the use
of protease inhibitors can provide protection against degradation (Ray 2011).
Regardless of various pre-analytical variables that may pose challenges in biomarker
discovery in blood, some of which are outlined above, there are undoubtedly several ways to
minimize the effects of such variables on proteomic analysis. One particular aspect to keep in
mind is the importance of maintaining uniformity in how every sample is treated within a sample
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set. Hence, when conducting serum or plasma proteomics research for biomarker discovery, care
should be taken in each stage of the study in order to maintain consistency in how samples are
treated, which will help reduce or minimize variability.

Dynamic Range Challenges in Blood Proteomics
In addition to pre-analytical variables, another substantial challenge that is encountered in
the use of blood (serum or plasma) specimens is the difficulty in observing less abundant
peptides in these complex mixtures due to the large dynamic range of protein/peptide
concentrations (around 10 orders of magnitude or more), where the large and highly abundant
proteins often mask the presence of lower abundance species (Walther 2010, Ray 2011). As a
result, significant ion suppression occurs, where the ion signal of less abundant species is masked
by the highly abundant species that have similar m/z ratios and retention times as the less
abundant ones (Rifai 2006). This is a significant issue because many disease-related protein
biomarkers as well as markers that reflect the pathophysiological state of tissues in the body are
often present in low abundance in blood, therefore it is necessary to perform fractionation,
protein depletion, or additional processing to visualize the lower abundance proteome (Ray 2011,
Araujo 2008).
The 22 most abundant proteins in the serum proteome have been shown to represent
approximately 99% of the total protein content of serum (Ray 2011, Merrell 2004, Tirumalai
2003). Of those 22 proteins, the top six include large proteins such as albumin, IgG, IgA,
haptoglobulin, transferrin and anti-trypsin proteins (Ray 2011, Tirumalai 2003). The remaining
1% of the serum protein content is thought to consist of low abundance proteins that have been
given great interest in proteomics studies for potential biomarkers (Tirumalai 2003).
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It has been suggested that disease markers, which often represent leakage or secretion
from live tissue or cells into the blood, are present in low concentration in the serum or plasma
due to the massive dilution that occurs as they enter circulating blood volume (Rifai 2006). The
large dynamic range in serum or plasma specimens exceeds the analytical ability of commonly
used MS systems and proteomics methods, which makes it challenging to detect lower
abundance proteins (Tirumalai 2003), and is perhaps one of the reasons why despite its clinical
importance, the serum or plasma proteome still remains incompletely characterized (Anderson
2002).

Lower Molecular Weight Species in Blood
In addition to disease biomarkers being at low abundance, these protein or peptide
markers, which are likely to reflect an underlying cell or tissue state, are often smaller, with
lower molecular weights (MW) (Tirumalai 2003). It is estimated that blood serum typically
consists of approximately 10,000 different proteins, with the majority being low molecular
weight species (Adkins 2002). This suggests that the low MW serum or plasma proteome
contains an unexplored archive of potentially useful disease detection marker information
(Tirumalai 2003). Low MW species often originate from proteolytic cleavage of larger species in
blood (Davis 2007), and may provide some information regarding disease mechanisms or
physiological changes in the organism (Petricoin 2002).
Many low abundance and low MW proteins/peptides in serum bind non-covalently to
large and highly abundant proteins that act as a carrier protein to form a biomarker-carrier
complex (Araujo 2008, Chertov 2004, Tirumalai 2003). For instance, albumin, which is the most
abundant large protein in blood often functions as a carrier protein that binds and transports
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physiologically important molecules such as hormones, cytokines, or lipoproteins (Veenstra
2005, Tirumalai 2003). In their unbound stage, low abundance/low MW biomarkers are filtered
from the bloodstream through the kidneys to be excreted from the body (Araujo 2008).
Conversely, studies have also indicated that carrier proteins are generally cleared more slowly
from the system (Araujo 2008). Therefore, it can be concluded that the non-covalent association
of biomarkers to carrier proteins protect against renal filtration of important biofunctional
molecules due to the longer half-life of the carrier proteins, thereby allowing these smaller
factors to be present in the bloodstream for a longer period of time (Araujo 2008).
Because of the detection limitations of a mass spectrometer, prior elimination of these
large and highly abundant proteins is essential to overcome their masking effect and to be able to
observe the low MW/low abundance molecular species in serum (Ray 2011). However, because
many of the small and low abundance proteins or peptides of interest may be bound to these
large carrier proteins, specific techniques should be implemented in order to minimize biomarker
loss that may otherwise occur when large carrier proteins along with their low abundant/low MW
cargo proteins are depleted from the specimens.

Large/Highly Abundant Protein Depletion Approaches
The main reason for the implementation of protein depletion strategies is to reduce the
dynamic range and complexity of serum proteins and to increase the ability to observe low
abundance/low MW molecules through the removal of large and highly abundant proteins (Ray
2011). This is one of the main determinants of success in the detection of low abundance disease
markers (Ray 2011).
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Various protein depletion approaches have been tried in the past. One such approach is
the use of antibody-based affinity columns to selectively remove the most abundant serum
proteins such as albumin, haptoglobulins, transferrins, α-1-antitrypsin, α-1-acid glycoprotein,
hemopexin, and α-2-macroglobulin (Veenstra 2005, Tirumalai 2003, Chertov 2004). Another
depletion approach is solid phase extraction, which involves dye-ligand binding, antibody-based,
metal chelating, and ion-exchange techniques (Ray 2011). An ideal depletion method should not
only eliminate highly abundant proteins, but should cause the dissociation of low
abundance/smaller peptides from carriers (Tirumalai 2003). However, neither of these
approaches protects against the loss of potentially diagnostic low MW/low abundance
proteins/peptides as a result of biomarker-carrier interaction.
Another depletion approach used in the proteomics field is centrifugal ultrafiltration. This
approach may or may not involve the use of specific solvent conditions that serve the purpose of
disrupting protein-protein interactions to promote the release of low MW molecules that may be
bound to the large proteins. Molecular weight cutoff filters eliminate higher MW proteins and
limit analysis to the low molecular weight proteome lower than a specific molecular weight cut
off (Tirumalai 2003). Some drawbacks of this approach include the possibility of losing some
diagnostically important species that are larger than the cutoff filter, pore size, as well as the cost
of such filtration systems.
Another depletion approach involves the use of an organic solvent, such as acetonitrile,
as a serum precipitant for large and highly abundant proteins. The use of acetonitrile has been
shown to effectively eliminate large and highly abundant proteins such as albumin (Chertov
2004). This approach is also superior to other depletion approaches such as affinity methods
because the acetonitrile also causes the dissociation of small molecules from the large proteins,
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thereby allowing the peptides and small proteins to be visible for mass spectrometry analysis
(Merrell 2004).

Combination of Tissue and Blood Biomarker Studies
More and more studies have indicated the potential value of combining multiple
biological specimens for biomarker studies. For instance, a combination of tissue and blood
biomarker studies could be valuable in gathering specific disease information from the disease
site as well as information regarding other physiological changes that may be visible in
peripheral fluids.
Figure 1.5 (taken and modified from Blonder 2011) describes some advantages and
disadvantages of blood and tissue markers in disease studies such as cancer. Because each type
of biological sample has specific advantages and disadvantages, the combination of multiple
specimens may provide complimentary information.

Summary
Over recent years mass spectrometry has become the most highly used and useful tool for
proteomics research, especially for disease biomarker discovery. However, due to the
development of various types of mass spectrometry instrumentation, discovery and identification
approaches, as well as advancements in our current understandings of the types of biological
specimens that can be used for biomarker discovery, it is beneficial to identify the desired
research outcome and work to develop those approaches and workflows to be used to minimize
variability and achieve the desired outcome.
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Figure 1.5 Advantages and disadvantages of tissue and peripheral fluid (such as plasma or serum)
biomarkers for disease studies. (Taken and modified from Blonder 2011).
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In our current studies that will be reported here, we use serum and tissue as our biological
specimens for methods development, biomarker discovery in a top-down proteomics strategy to
investigate the low MW proteome of these two biological specimens, and for biomarker
sequencing and/or chemical identification. An acetonitrile precipitation approach is used for the
depletion of large and highly abundant proteins while preserving and liberating the low
abundance/low MW species that are attached to these large carrier proteins. The details of our
research are reported in the subsequent chapters.
The second chapter gives an outline of a novel tissue proteomics method that we have
recently developed for the investigation of low MW proteins/peptides of tissue. This method is a
modification of a serum proteomics approach that has been previously published from our lab
(Merrell 2004). The third chapter will detail the use of our approach in determining amino acid
sequences or identities of biomarkers found to be statistically significant in diagnosing
preeclampsia from non-preeclamptic pregnancies at 12-14 weeks of pregnancy. The fourth
chapter discusses our endometriosis biomarker discovery study and biomarker identification of
potentially promising diagnostic markers.
We acknowledge that although the tissue proteomics method may show some promise,
and potential serum biomarkers have been found and identified in our research on these various
diseases, there is still a need for validation of our findings to strengthen and confirm these
results. Regardless, we believe that our findings show substantial promise in further
understanding disease diagnosis using tissue and serum as materials for biomarker discovery.
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2. Chapter 2 - Tissue Proteomics of the Low-Molecular-Weight Proteome Using an
Integrated cLC-ESI-QTOFMS Approach

Abstract
Analysis of the protein/peptide composition of tissue has provided meaningful insights
into tissue biology and even mechanisms of tissue-related diseases such as cancer or
endometriosis, among others. However, little has been published regarding top down methods to
investigate lower molecular weight (MW) (500-5000 Da) species in tissue. Here we evaluate a
tissue proteomics approach involving tissue homogenization followed by depletion of large
proteins and then capillary liquid chromatography-mass spectrometry (cLC-MS) analysis to
interrogate the low MW/low abundance tissue proteome. In the development of this method,
sheep heart, lung, liver, kidney, and spleen were surveyed to test our ability to observe tissue
differences. After categorical tissue differences were demonstrated, a detailed study of this
method’s reproducibility was undertaken to determine whether or not it is suitable for analyzing
more subtle differences in the abundance of small proteins and peptides. Our results suggest that
this method should be useful in exploring the low-MW proteome of tissues.

Introduction
Proteomic mass spectrometry has frequently been employed to investigate tissue proteins.
The most commonly used method for exploring the tissue proteome is two-dimensional gel
electrophoresis to isolate differentially expressed proteins between specimens, followed by their
isolation, tryptic digestion, and analysis by matrix-assisted laser desorption ionization mass
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spectrometry (MALDI-MS) [Iwadate 2008, Person 2006]. Another approach commonly used for
marker discovery is shotgun proteomics, where all the protein content of the matrix is
enzymatically digested and the resulting complex mixture of peptide fragments are then analyzed
and sorted via chromatography and MS [Han 2008, Gstaiger 2009]. While these approaches have
proven to be useful in surveying many proteins in biological matrices, it is more often highly
abundant cytoskeletal, fibrous, or ribosomal proteins that are observed [Gstaiger 2009]. Many of
these have more of a structural or housekeeping function and hence may provide limited
physiological or disease-related information. This suggests the need for the development of other
methods to detect and investigate other cell components, e.g. the low-molecular weight species
in tissue which are likely to provide more meaningful disease-related information, through the
removal of the large and highly abundant species [Adkins 2002, Govorukhina 2003].
Several abundant-protein depletion strategies have been employed over the years, such as
immunoaffinity depletion, centrifugal ultrafiltration, fractionation methods such as size exclusion
chromatography, etc [Merrell 2004, Rifai 2006]. While these approaches can be very effective in
separating large proteins from smaller molecules in a complex mixture, there is still a large
portion of the low molecular weight proteome that is lost due to their binding or non-covalent
interaction with large carrier proteins to form biomarker-carrier complexes [Merrell 2004,
Tirumalai 2003, Araujo 2008]. Therefore, as the carrier proteins are depleted from the mixture,
many low molecular weight species that could be informative in disease studies, are likely to be
removed as well.
Recently, a proteomic approach utilizing capillary liquid chromatography (cLC) of
protein-depleted serum coupled through electrospray ionization (ESI) directly to
quadrapole/time-of-flight mass spectrometry (QTOFMS) has been published [7]. This approach,
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in part, follows the logic that when dealing with complex biological mixtures, it is often
beneficial to utilize targeted strategies for biomarker discovery to reduce specimen complexity
[Davis 2010, Walther 2010], such as targeting the low molecular weight proteome of the
biological matrix. This targeting was accomplished through an acetonitrile precipitation step of
serum samples to remove the large and highly abundant proteins, many of which are often
uninformative for biomarker discovery purposes [Merrell 2004, Merrell 2008]. This approach
has also shown that the addition of acetonitrile disrupts the binding of smaller molecules to large
carrier proteins, causing their dissociation from the carrier proteins, which increases the number
of low MW species observed via cLC-MS as compared to other commonly used protein
depletion approaches [Merrell 2004, Chertov 2004].
In addition to increasing the number of low MW species being observed, this cLC-ESIQTOFMS approach also overcomes limitations of several previously used proteomic approaches
in two additional aspects. First, it provided a means to analyze low abundance, low molecular
weight species via cLC-MS that wouldn’t be observed in 2D gel electrophoresis. Second, the use
of protein depletion via acetonitrile allowed for the analysis of peptides and other small
molecules in the sample that would otherwise be masked and rendered unobservable in the MS
step by the presence of the large and more highly abundant proteins due to ion suppression.
Thus, this low MW serum proteomics method overcame some of these issues and provided
insight into certain disease-specific markers present in human serum [Esplin 2011].
Our hypothesis was that an adaptation of this technique would also be applicable to
tissue, allowing for the determination of lower MW species’ biochemistry in cells or tissues. The
ultimate goal of this work was to provide a tool that could be used in the exploration of potential
disease-related biomarkers in tissue. The rationale behind this goal was that targeting biomarkers
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at the diseased-tissue level itself may reveal higher or lower levels of specific markers of interest
as the tissue is the source of these markers, and the levels of markers are likely to diminish with
further distance from the diseased tissue due to dilution into the blood stream [Rifai 2006, Davis
2010]. In this initial evaluation, we report on the reproducibility and usefulness of a cLC-ESIQTOFMS approach in the analysis of lower MW species in tissue.

Materials and Methods
Tissue Homogenization
In our first comparison, samples of heart, liver, kidney, lung, and spleen obtained freshly
from a single sheep were kept frozen until homogenization by ball mill. Stainless steel surgical
blades were used to produce thin shavings of the frozen tissue specimens and to mince them
further on a sterilized glass dish. Approximately one gram of tissue was placed into the stainless
steel dismembrator capsule (Sartorius Mikro-Dismembrator S) along with 15 to 18 stainless steel
balls. The capsule was immersed in liquid nitrogen for approximately 4 min to freeze its
contents. Upon freezing, the capsule was shaken for a minimum of 8-12 min at 2000 RPM. If the
specimen was not thoroughly homogenized, the capsule was flash-frozen and shaken again for a
second time. Thoroughly homogenized specimens were stored in a fresh tube and kept frozen
until further processing. The immediate freezing of tissue and its processing while frozen
minimizes proteolytic degradation.
In the second set of evaluations we obtained spleen samples freshly from six additional
sheep to test the reproducibility of this tissue proteomics approach across several animals. These
follow-up specimens were subjected to the same tissue homogenization and processing steps
described above.
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Post-Homogenization Processing
Portions of homogenized tissue were processed further. One gram of tissue homogenate
was resuspended in 10 mL of 1X phosphate buffered saline (PBS), and the tissue homogenatePBS mixture was vortexed for 30 sec until thoroughly mixed. The mixture was then centrifuged
(Sorval RT7, Kendro Laboratory Products, Newton, CT) at ~3000 xg for 10 min to remove any
debris insoluble in PBS. The pellet was discarded. The remaining supernatant was aliquoted into
200 µL aliquots. One aliquot is taken for further processing, with the remainder stored at -80oC
and thawed as necessary.

Acetonitrile Precipitation
Acetonitrile was used to eliminate high abundance, high molecular weight proteins as
described previously (Merrell 2004). Briefly 400 μL of acetonitrile were added to 200 μL of
supernatant (2:1 ratio of organic solvent to supernatant), mixed via vortexing and allowed to sit
at room temperature for 30 min. The mixture was centrifuged at 14,000 rpm (IEC Micromax
RF, Thermo Fisher Scientific, Waltham, MA). The pellet, containing the large and highly
abundant portion of the specimen was discarded, leaving a supernatant containing low molecular
weight protein and peptide species. The supernatant (~550 µL) was then transferred to a fresh
microcentrifuge tube containing 300 µL of HPLC grade water and mixed thoroughly. The
volume was reduced to ~200 µL in a vacuum centrifuge (CentriVap Concentrator Labconco
Corporation, Kansas, City, MO) to eliminate any remaining organic solvent in the mixture, and
the apparent protein concentration was determined using a Bio-Rad microtiter plate protein
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assay, performed following the manufacturer’s instructions (Bio-Rad Laboratories, Hercules,
CA). A volume of the protein-depleted homogenate, equivalent to 4 µg apparent protein, was
transferred into a fresh microcentrifuge tube and lyophilized (CentriVap Concentrator Labconco
Corporation, Kansas, City, MO) to less than 20 µL. Samples were then brought up to a volume
of 20 µL by adding HPLC grade water and acidified through the addition of 20 µL of 88%
formic acid.

cLC Separation for MS Analysis
Capillary liquid chromatography (cLC) was performed to fractionate the sample. The
cLC system employed a 1 mm (16.2 μL) microbore guard column (Upchurch Scientific, Oak
Harbor, WA) and a 15 cm x 250 μm i.d. capillary column assembled in-house. The guard
column was dry-packed and the capillary column was slurry packed with POROS R1 reversedphase media (Applied Biosystems, Framingham, MA). We performed column equilibration and
chromatographic separation using an aqueous phase (98% HPLC grade H2O, 2% acetonitrile,
0.1% formic acid) and an organic phase (2% H2O, 98% acetonitrile, 0.1% formic acid). Elution
started with 3 min of a mobile phase containing 95% aqueous phase and 5% organic phase,
followed by a linear increase to 60% organic phase over 24 min. The gradient was then increased
to 95% organic phase over 7 min, held at 95% organic for 7 min and returned to 95% aqueous
phase over 5 min and held there to re-equilibrate the column. The flow rate was 5.0 μL/min.
The cLC used an LC Packings Ultimate Capillary HPLC pump system, with a FAMOS®
autosampler (Dionex Corporation, Sunnyvale, CA) and was controlled and results recorded using
Analyst QS® 1.1 software (Applied Biosystems, Foster City, CA).
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MS Analysis
The cLC system interfaced a QSTAR Pulsar I quadrupole orthogonal time-of-flight mass
spectrometer through an IonSpray source (Applied Biosystems) set at 4800V. All experiments
were done in positive ion mode. The data were collected for m/z 500 to 2500 from 5 to 55 min of
the cLC elution with mass spectra obtained every 1 sec. The elution profile of each cLC
fractionated sample was reported as the total ion chromatogram (TIC).

Peptide Sequencing Using MS/MS with QSTAR Pulsar I Quadrupole Orthogonal Time-ofFlight Mass Spectrometer
Previously run MS spectra were inspected to find samples that had a high abundance of a
peptide of interest. Frozen supernatant of those specimens was thawed and a supernatant sample
containing 0.5 µg protein was transferred to a fresh microcentrifuge tube and 2.5 µL of 88%
formic acid was added. The specimens chosen for MS/MS analysis were manually injected onto
the cLC-MS. MS/MS fragmentation data were collected from m/z 50 to 2000 during the relevant
elution interval, typically 2 min in duration. N2 was used as the collision gas. Multiple runs at
various collision energies were used to produce different fragments of the peak of interest.
Collision energies were optimized with larger peptides fragmented typically at higher energies.
All spectra from all collision energies were overlaid and summed, giving a single MS/MS
spectrum. We visually inspected the summed spectrum and compared it to the exported data list
to correct any miss-assigned charge states. All peaks in the adjusted data list were transformed
into their +1 m/z values using the formula: +1 mass = m/z value * charge – (charge – 1H+) to
simplify the database search. This corrected mass list was exported as a tab-delimited text file
and submitted to Mascot (Mascot 2.3, www.matrixscience.com). The parameters used for
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Mascot searches were no enzyme digestion, SwissProt database, no modifications, peptide
tolerance of 1.2 Da, and MS/MS tolerance of 0.6 Da. Furthermore, the Mascot search results
were cross-checked against a protein Blast search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) or
other databases to confirm our findings.

Peptide Sequencing using MS/MS with LTQ-Orbitrap XLTM Hybrid Mass Spectrometer
In instances where an amino acid sequence could not be obtained using the QStar
instrument, we also utilized an LTQ-Orbitrap XLTM for amino acid sequence determination. In
the Orbitrap experiments, capillary liquid chromatography used a 75 µm x 100 mm nanoAcquity
UPLC® BEH300 column with reversed-phase 1.7 µm C4 particles (Waters Corporation, Milford,
MA). The sample was loaded onto a 3 µm C4 guard column (Optimize Tech, Oregon City, OR)
in a 95% buffer A (97.9% H2O + 2% ACN + 0.1% formic acid) and 5% buffer B (99.9% ACN +
0.1% formic acid) for 10 minutes at a flow rate of 400 nL/min. Elution was accomplished
beginning at 95% aqueous buffer A and 5% organic buffer B and increasing the organic phase to
60% over 50 min. Over the next 10 min, the organic phase was increased to 95% and maintained
at this level for 10 min. The organic phase was then reduced to 5% over 10 min and maintained
there for 20 min to re-equilibrate the column. The flow rate used during the second step was 300
nL/min. Separations were performed on nanoLC-Ultra chromatographic system (Eksigent,
Dublin, CA) and controlled by the mass spectrometer software (Excalibur, Thermo Scientific).
The cLC was coupled directly to the mass spectrometer and the effluent was sprayed using a
nano-capillary silica tip with 10 µm inner diameter (I.D.) and 360 µm outer diameter (O.D.) into
a double orthogonal inlet and transported through a radio frequency (rf)-only guide quadrupole
(Thermo Masslab Ltd., Manchester, U.K.). A specimen containing 0.1 µg apparent protein was
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loaded onto the column and data dependent tandem mass spectrometry (MS/MS) analysis was
performed using an LTQ-Orbitrap XLTM hybrid mass spectrometer (ThermoFisher, San Jose,
CA) to fragment the peptide. Full MS spectra were acquired in profile mode with a mass range of
m/z 400-2000, either in the Orbitrap analyzer with resolution set at 60,000 (with disabled
preview scan mode), or in the LTQ using the normal scan rate, and followed by four MS/MS
events in the linear ion trap. To prevent repetitive analysis, dynamic exclusion was enabled with
a repeat count of 3, a repeat duration of 30 sec, an exclusion list size of 500 and exclusion
duration of 120 sec. MS scan functions and UPLC gradients were controlled by the Xcalibur data
system (ThermoFisher). All tandem mass spectra were collected using a normalized collision
energy of 35% and an isolation width of 2 Da. Microscans for full scan in Orbitrap and LTQ
were 1 and 3 respectively and were applied for all experiments in Orbitrap or LTQ. Maximum
injection times for full scan in the Orbitrap and LTQ were 10 msec and for MSn scans were 100
msec and 120 msec respectively. The AGC targets for LTQ and Orbitrap are 2e4 and 1e6 (full
scan); 1e4 and 1e5 (SIM scan); and 5e3 and 2e4 (MSn scan).
The raw data files were then converted using the software program “msconvert.exe”
(ProteoWizard release 2.1.2575, http://proteowizard.sourceforge.net/) into the mzXML format.
We further used an extracting algorithm to extract selected scans that showed fragmentation
results for the peptide of interest. The extracted file was uploaded on the MASCOT search
engine to determine the sequence identity of the peptide.
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Comparison of Apparent Protein Concentration Before and After Acetonitrile
Precipitation
In our initial observations, a Bio-Rad microtiter plate protein assay following the
manufacturer's guidelines (Bio-Rad Laboratories, Hercules, CA) was performed on supernatants
of tissue homogenates before and after the organic precipitation step. This was done to confirm
the removal of the large and highly abundant species in tissue through acetonitrile precipitation.
The apparent concentrations of specimens before and after precipitation were determined and
reported.

Comparison of Serum and Tissue LC-MS
Because this tissue proteomics method was developed from a previously described serum
proteomics method, it was of interest to compare the chromatograms of specimens originating
from serum and tissue, as well as determine the complexity of the low MW proteome of tissue
compared to the low MW serum proteome as observed in the LC-MS chromatograms. To test
this, bovine serum, human serum, and sheep tissue were run on LC-ESI-TOFMS. The
chromatograms of these specimens were compared and the peak counts were determined.

Initial Proteomic Evaluation: Analysis of Differences and Similarities Across Tissue-Types
The first question addressed in the evaluation of this tissue proteomic method was
whether this approach can identify categorical differences, i.e. tissue specific peptides. To do
this, we analyzed overlays of mass spectra from five different tissues (heart, lungs, liver, kidney,
and spleen), each assigned a different color to distinguish tissue types on the composite spectra
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for comparisons. One two-minute elution window (from 16 to 18 min) was used to address the
question. This two-minute window was chosen because of a higher number of peptides observed.
Specific peaks were selected based on visual differences observed across the different tissue
types from the spectra overlay. Peak heights were determined using the Analyst QS® software
and recorded for comparison purposes.

Second Proteomic Evaluation: Reproducibility
The second goal of this research was to determine the reproducibility of this method to
know whether this approach could be used to detect more subtle quantitative differences between
comparison groups. To this end, we assessed the reproducibility of this approach at varying
stages of tissue processing/analysis. These reproducibility studies were conducted using sheep
spleen as a representative tissue. This also allowed us to use peaks present exclusively in spleen
as our index molecules (peptides m/z 1179, 1185, and 1213) and made the number of peptides to
be sequenced manageable. These 3 peaks are hereafter referred to as 'spleen peptides'. As in all
our studies, the analyses used peak heights of each peptide averaged over all of their observable
charge states. Peak heights were reported as the mean ± 1 standard error.
Reproducibility at four stages in our general experimental workflow was evaluated,
starting with sheep spleen which was subjected to tissue homogenization, followed by
acetonitrile precipitation, and cLC-MS analysis. We began our assessment by first comparing
specimens at the cLC-MS step and then worked backwards through additional steps as outlined
in Figure 2.1.
The first assessment determined reproducibility of cLC-MS runs of a single specimen of
protein-depleted ovine spleen homogenate analyzed by LC-MS on 4 consecutive days. The
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Figure 2.1 An outline of the reproducibility steps performed in this study
(1) represents the first reproducibility assessment involving LC-MS runs of the exact same sample from one spleen,
one homogenate and one protein depleted step on multiple days, (2) represents the second reproducibility
assessment where several protein depleted samples from one homogenate of one spleen were analyzed, (3)
represents the third reproducibility assessment involving several samples originating from multiple homogenates of
a single spleen, and (4) represents the final reproducibility assessment of specimens from several sheep spleens.
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second assessment determined reproducibility of cLC-MS analysis of specific spleen peptide
levels when 5 separate protein-depleted specimens were prepared from a single homogenate and
each run by cLC-MS on a different day. Again, spleen peptide levels were measured in
duplicate. The third assessment considered duplicate runs of several different homogenates
prepared from a single spleen. Each homogenate was individually submitted to protein-depletion
and cLC-MS analysis on different days. Again the index spleen peptide intensities were
monitored. Lastly, in the fourth assessment of variability, we used spleens from six different
sheep, processed individually as described above and each analyzed on a separate day in
triplicate by cLC-MS. The same index peptides were monitored.

Data Normalization Approaches to Potentially Reduce Variability
The next set of studies applied different data normalization strategies in an effort to
reduce data variability. In the last stage of the reproducibility assessment (described above), it
was observed that peptide m/z 1213 had a relatively higher coefficient of variation compared to
the other spleen peptides and data normalization methods were explored to reduce the variability
of this index peptide.
We compared the un-normalized peptide m/z 1213 levels with peptide m/z 1213 levels
normalized to six types of references, including 1) an external standard run on the same day but
independently of our tissue samples, 2) an external standard spiked into the tissue sample, 3)
total ion current (TIC), i.e. the average area under the curve over all the spectra [Sauce 2004], 4)
the base peak, which is the highest point of the TIC, 5) total counts excluding the signal from the
dead volume of the column and signal observed during washout, and 6) an endogenous peptide
present at comparable levels in all tissues evaluated.
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The first reference used for normalization was Glu-fibrinopeptide B (GluFib), a nonphysiologic peptide standard of known mass, run daily for instrument calibration purposes. Peak
height values of GluFib were obtained for all the days when the tissue specimens were run, and
the ratio of peptide m/z 1213 to GluFib intensities was calculated to yield the normalized peptide
1213 levels.
With regard to GluFib as a reference for normalization, we also attempted to spike
GluFib into the specimen rather than using it as an external reference. GluFib was spiked into
each specimen, submitted to cLC-MS analyses and the spiked GluFib intensities were used to
normalize peptide 1213 levels.
For the third normalization approach data were normalized by dividing the intensity of
peptide m/z 1213 in each specimen by the respective total ion counts.
In the fourth approach we selected the base peak or the highest point in the
chromatogram and recorded the total counts for that specific elution time. The intensity of
peptide m/z 1213 was divided by that number.
For the fifth reference, the total counts, excluding the dead volume (~>15 min) and
washout phase (~<34min), were determined and used to normalize the peptide m/z 1213.
The sixth reference was the molecular species at m/z 583 which was a peak observable in
all the tissue specimens studied. Criteria for selection are described below.
In addition to testing the effect of data normalization using these six different
normalization references on peptide m/z 1213, which had the highest un-normalized coefficient
of variation, we also used these same six references on index peptide m/z 1185 which had the
lowest un-normalized coefficient of variation. This was performed in order to compare the effect
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of normalization on these two index peptides and to determine the possible reason of variability
observed in this study.

Reference Peptide Selection Criteria
The selection was based on the following: First, the reference peak must be present in all
samples analyzed in readily detectable amounts, preferably having a lower charge state (+1 or
+2) to minimize peak overlap and problems in determining peak amplitude. Second, the
reference peak should not occur in a region of high baseline noise. Third, the reference peak
must exist in comparable quantities across all specimens. Fourth, the reference peak would
ideally elute at a similar time to the peptide of interest. Clearly, when a target peptide has been
chemically identified, later studies can include a synthetic heavy isotope analogue to allow for
absolute quantitation.
Although these criteria provide guidelines, in reality, there can be many suitable
candidates or it may be challenging to find one that fulfills all the criteria we have established.
For instance, there may be occasions where one is unable to find a reference peptide that eluted
at a similar time as our peptides of interest. In that situation, we may have to settle for a
reference peak further away from the elution time of our peptides of interest. Thus, although
these criteria may provide a general guideline to determine reference peaks for normalization,
they should not be considered as strict rules because there are undoubtedly many instances where
these criteria may not be applicable.
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Statistical Analysis
Peptide intensities were provided as the mean + SE (standard error). In order to assess
the reproducibility of this tissue proteomics method at different stages, the coefficient of
variation (CV) was calculated. Comparisons of the CVs of different normalization approaches
was accomplished using Student's T-test. A p-value of < 0.05 was considered significant.

Results and Discussion
Comparison of Apparent Protein Concentration Before and After Acetonitrile
Precipitation
The primary reason for the acetonitrile precipitation step in our approach is to eliminate
the large and highly abundant proteins from specimens, thereby allowing us to focus our analysis
on the low abundant/low molecular weight proteome, which may be otherwise unobservable in
the presence of the large and highly abundant species. In our previous analysis in serum, which
was the original specimen used to develop this proteomics approach, we were able to observe
effective elimination of a large portion of the serum proteome. However, for the purpose of
testing the effectiveness of this method in the removal of large/highly abundant protein in tissue
specimens, we also tested this in our tissue specimens. The protein concentration measurements
of the different tissue types before and after the precipitation step revealed that we were able to
remove approximately 92% of the apparent protein content in the various tissue specimens
through this precipitation step as shown in Figure 2.2.
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Elimination of Large/ High Abundance Proteins

Protein Concentration (ug/uL)

2.5
2
1.5
1
0.5
0
spleen no spleen ppt kidney no kidney ppt liver no ppt
ppt
ppt

liver ppt

lung no ppt

lung ppt

heart no
ppt

heart ppt

Tissue Type With or Without Precipitation

Figure 2.2 Comparison of apparent protein concentration before and after acetonitrile precipitation
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Comparison of Sheep Tissue, Bovine Serum, and Human Serum cLC Runs
The general proteomics approach considered here has been previously published for the
analysis of the low molecular weight proteome of serum [Merrell 2004]. However, it was of
interest to know the breadth and complexity of the low molecular weight tissue proteome and the
potential utility of capillary LC-ESI-TOFMS analysis to identify potential molecular expression
differences between different comparison conditions. Comparisons of our initial tissue runs with
previous runs of bovine and human serum revealed differences in peak counts. In our serum MS
runs we generally observed an average of ~8000 peaks in the evaluated portion (10 two minutes
elution intervals) of the 55 minute cLC-MS runs. In our tissue MS runs, an average of ~7300
peaks was observed for the same evaluated time. There were also differences in the general
contour of the TIC of the chromatograms (Figure 2.3), with a substantially greater number of
ions from tissue eluting early in the chromatogram compared with serum. This suggests the
presence of smaller and more hydrophilic species in tissue specimens compared to serum
specimens.

Differences and Similarities Across Tissue-Types
For tissue peptidomics to have value, tissue specific differences in protein and peptide
expression should be easily observable. As a representative test of this proteomic approach, we
chose a single two-minute elution window.
Comparing mass spectra of this region for the five tissue types, we observed many tissuespecific peaks although the majority of peaks were similar across all tissue types. A few
examples are reported in Table 2.1 (bold font was used to emphasize organs in which these
peptides appeared to be present in greatest abundance). The first three peaks in the table are
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Figure 2.3 A comparison of sheep spleen, bovine serum, and human serum cLC-MS runs following the
protein-depletion steps.
The top panel shows the TIC of a sample chromatogram of splenic tissue, while the middle panel shows a sample
chromatogram of bovine serum and the bottom panel shows a sample chromatogram of human serum submitted to
cLC-MS analysis after protein depletion.
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Table 2.1 Peptide Peak Intensity (Counts) by Tissue *
MW

(Charge)

Spleen

Heart

Lung

Kidney

Liver

1. 1213.28

(+3)

1651

87

249

385

155

2. 1179.5

(+3)

1120

134

110

81

281

3. 1185.08

(+2)

2140

126

164

127

232

4. 1442.83

(>+7)**

88

3079

91

531

140

5. 669.2

(+5)

1205

298

2235

1766

804

* The general baseline ranged between 30 and 60 counts
** The charge state of >+7 was used to described an unresolved isotopic envelope
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molecular species that appeared to be in the highest or greatest concentration in sheep spleen,
and hardly present in the other tissue types. The fourth peak in the table represented a molecular
species that appeared to be in the highest concentration in sheep heart, present in small amounts
in sheep kidney, and almost undetectable in the other tissue types. The fifth peak in Table 2.1
represents an example of a molecular species that was visibly present in all the tissue types
studied.
Additionally, we also overlaid the mass spectra of this elution window representative of
the different organs to visualize the different levels of these peptides across tissue types (Figure
2.4). Figure 2.4A presents levels of the first three peaks listed in Table 2.1, which were almost
exclusively present in spleen. Figure 2.4B displays an overlay of the same five specimens from
Figure 2.4A showing the fourth peak of Table 2.1, which was present in heart and kidney, but
generally not observed in the other tissue types.
The majority of ionic species appeared to be present in all tissue types. One such peak
(the fifth peak listed in Table 2.1) is illustrated in Figure 2.4C. Taken together, these data suggest
the ability of this tissue proteomics approach to find tissue-specific peptide/small protein
differences across various tissue types.
In addition to being able to detect such categorical differences, an ideal tissue proteomic
approach should also be able to distinguish more subtle quantitative differences across
comparison groups. To be able to do this, variability must be sufficiently low to allow for
differences to be demonstrated. To test this, we conducted reproducibility assessments on sheep
spleen following the various steps described in the Methods section.
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Figure 2.4 Mass spectral overlay of five different tissue types demonstrating differences or similarities in
molecular species composition.
The figure is color coded with spleen in light green, heart in blue, lungs in dark green, kidney in purple, and liver in
red. (A) The molecular species at 1179, 1185 and 1213 (m/z) appear to be present in higher mounts in spleen (light
green) compared to other tissue types. (B) The molecular species at 1442 (m/z) appears to have a much higher
intensity in heart (blue), visibly present in low amounts in kidney (purple), and hardly detected in the other tissue
types. (C) The molecular species at 669 (m/z) appears to be present in differing amounts in all the tissue types.
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Reproducibility Studies: Assessments of Variability at Four Stages of Processing/Analysis
In the first reproducibility test, the same fully processed spleen sample was run on four
separate days, and the peak intensities as well as the CV of the spleen peptides determined
(Figure 2.5A). When submitted to the cLC-MS, day-to-day mass spectral analyses revealed
approximately 25% -50% variability of the three index peptides without normalization. It is
likely that day-to-day instrument performance or other factors such as specimen processing or
peptide degradation contributed to such variability.
In the second assessment of variability, we analyzed five different samples originating
from the same homogenate but each processed separately and each submitted to MS on different
days. For the 3 spleen peptides’ unnormalized intensities we observed an average variability of
24% (Figure 2.5B).
In the third reproducibility assessment, unnormalized levels of the 3 index spleen
peptides in specimens originating from a single spleen but from different homogenization
batches run on different days were measured and reported in Figure 2.5C. As in the first two
reproducibility assessments, variability of approximately 25% was found.
In the final reproducibility assessment, unnormalized levels of these index spleen peptides
sampled from six different spleens from six different sheep run on different days were
determined (Figure 2.5D). The CVs for the index peptides averaged ~30%. As can be seen in
Figure 2.5D, peptide m/z 1185 appeared to have the lowest coefficient of variation (CV=11.6%)
and peptide m/z 1213 had a relatively higher coefficient of variation compared with the other
spleen peptides (CV=47.5%).
The results of these four assessments suggested that the use of unnormalized peak
intensities revealed somewhat consistent variability with CVs of 30% on average. The variability
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Figure 2.5 Measurement of peptides m/z 1179, 1185, and 1213 to determine method reproducibility.
(A) Un-normalized spleen peptide levels from the same samples ran on different days. (B) Un-normalized spleen
peptide levels in different precipitations from the same homogenate, where each bar represents one specimen within
the same homogenate. (C) Un-normalized spleen peptide levels from different homogenates, where each bar
represents a sample from one of the three homogenates being analyzed (D) Un-normalized spleen peptide levels
from six different sheep spleens, where each bar represents peptide levels from each sheep.

55
could be due to variable processing and instrument performance. As such, normalization
methods were tested for their ability to improve reproducibility. Six normalization approaches
were tried on the index peptide m/z 1213, which had a higher level of variability in the fourth
reproducibility assessment as well as the index peptide m/z 1185 with the lowest variability.

Data Normalization Approaches
The reproducibility in using un-normalized peptide m/z 1213 data (CV = 47.5) across six
sheep spleens was determined (Figure 2.5D) and compared to their normalized values using six
approaches.
In the first normalization approach we used Glu-fibrinopeptide B (GluFib) as a reference.
The peak height of GluFib, obtained by cLC-MS at the beginning of each day’s instrument
calibration, was used to normalize peptide m/z 1213 peak intensities run later that day and the
CV was calculated (Table 2.2). The CV of 122.9 showed that normalization with this external
reference peptide did not improve reproducibility.
In a separate experimental set, we also attempted the use of GluFib as a reference when
GluFib was spiked into specimens from multiple sheep spleens, yielding a coefficient of
variation of 68.3 (Table 2.3). Those findings suggested that spiking GluFib yielded a better CV
(Table 2.3) than GluFib as an external reference (Table 2.2). Nevertheless, the GluFib-spiked
normalized data set had a CV that was relatively similar to the un-normalized data for peptide
m/z 1213. Therefore, neither GluFib normalization approach appeared to improve
reproducibility.
Table 2.2 also shows the results of normalizing peptide 1213 peak intensities to each
sample’s respective total ion counts, the next approach attempted. In comparing the CV of un-
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Table 2.2 Peptide m/z 1213 Coefficient of Variation across Various Normalization Approaches
Reference peaks

1213 (CV)

None

47.5

GF

122.9

TIC

52.1

Counts at highest point

88.4

Counts without end noises

88.6

583

80.8
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Table 2.3 Peptides m/z 1185 and 1213 Coefficient of Variation Comparing No Normalization and
Normalization with Spiked GluFib
Reference peaks
none
GF (spike)

1185 (CV)
16.23
61.4

1213 (CV)
64.13
68.3
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normalized data (CV=47.5%) and data normalized to the total ion counts (CV=52.1%) we saw
no improvement in reproducibility. One possible concern in using the TIC for data normalization
is that the total ion current incorporates the counts obtained from both signal as well as noise. To
overcome this, we attempted a fourth data normalization approach where we used the base peak
for normalization (Table 2.2). This approach did not decrease variability (CV= 88.4%).
The fifth normalization approach removed regions of the TIC dominated by noise and
washout as described above. The CV was 88.6% (Table 2.2), demonstrating no improvement in
reproducibility.
For the sixth normalization approach, careful review of several mass spectra from
protein-depleted tissue was conducted to select several peptides that met the criteria established
for a species to serve as an endogenous reference peptide for data normalization. Of these, one
was chosen at random (a peptide at m/z 583) as a non-tissue specific internal reference to test
this concept for normalization of the target peptide (Table 2.2). The use of this endogenous nontissue specific reference peptide for data normalization yielded a CV of 80.8%, which provided
no reduction in variability in this data set. While these results were rather surprising, as
normalized data are typically expected to perform better than unnormalized data, our findings
could be explained in part by the low number of replicates used in the experiments.
To further test the effect of normalization, we also performed normalization on peptide m/z
1185, the peptide with the lowest CV (CV=11.6%) across 5 sheep (Figure 2.5D), using several of
the normalization approaches described above. The findings are reported in Table 2.4 and the
results indicated no significant improvement in variability when peptide m/z 1185 was
normalized using the six different approaches. These findings further argued that the variability
observed was likely a result of inherent biological variation because normalization of the most
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Table 2.4 Peptide m/z 1185 Coefficient of Variation across Various Normalization Approaches
Reference peaks

1185 (CV)

None

11.6

GF

61.5

TIC

12.5

Counts at highest point

71

Counts without end noises

67.5

583

51.7
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variable peptide (m/z 1213) or the least variable peptide (m/z 1185) using various normalization
approaches yielded no significant improvement in reproducibility.
When comparing Tables 2.2 and 2.4 (each table represents a different spleen-specific
peptide) a similar pattern can be observed. The coefficient of variation for those two peptides
were plotted versus the types of normalization used (Figure 2.6). As seen in Figure 2.6 below,
there appears to be a pattern for both peptides. For example, normalization with external GF
provided the highest CV. In each normalization peptide 1213 was still more variable. The poorer
reproducibility of 1213 may well reflect its biology. Overall the results fluctuate, perhaps
reflecting the merits of each normalization approach, with some of them, e.g. normalization to
TIC, appearing superior to other methods despite providing no significant improvement.
Taken together, these findings suggest that this tissue proteomics approach yields a
generally consistent level of variability (averaging around 30%) much of which appears to be
due to biological variation. Additionally, none of the methods of normalization tried here
significantly lower variability.

Fragmentation Analysis
We analyzed one spleen peptide (m/z 1185) by performing amino acid sequence determination
studies using the Orbitrap LTQ XL (Figure 2.7). Submission of the peptide fragmentation data to
Mascot identified the peptide as a fragment of desmin. Figure 2.7 lists the amino acid sequence
of 1185.
Because the peptide was identified in the bovine taxonomy, an additional search was
performed to determine its homology with ovine desmin. A National Center for Biotechnology
Information (NCBI) database search revealed 100% homology across the two taxa. Desmin is a
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Figure 2.6 Comparison of peptides m/z 1213 and 1185 CV values across six normalization approaches
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Figure 2.7 Amino acid sequencing by collision induced fragmentation of one of the spleen peptides having an
m/z of 1185.
Mascot search results of the fragmentation spectra indicating that the molecular species at peptide m/z 1185 is a
fragment of desmin.
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protein which has been shown to be expressed in fibroblastic reticular cells (FRC) in spleen
[Link 2007].
Additionally, the other two spleen peptides (peptides m/z 1179, and 1213) were
sequenced on the QSTAR instrument using several different collision energies following a
previously established method [Merrell 2009]. The peptide at m/z 1179 was identified as a
fragment of actin-2 originating from Echinococcus granulosus (e-value: 7e-17), which is a type
of tape worm commonly present in sheep (Figure 2.8). The peptide at m/z 1213 was identified as
a fragment of actin cytoplasmic 2 from the bovine taxon (e-value: 3e-21), which is identical to its
sequence in sheep (Figure 2.9).

Concluding Remarks
Analysis of the low molecular weight proteome of tissue has great potential to enhance
our understanding of cell and tissue biology. An extensive survey of the low molecular weight
proteome may allow for biomarker discovery or for better understanding of tissue-related disease
mechanisms, particularly because tissue-specific biomarkers will be present in the highest
concentration in the tissue itself, as compared to their levels in biological fluids [Blonder 2011].
Unfortunately, small biomarker discovery in tissue has not been attempted frequently perhaps
due to limited pathologic specimens, difficulty in obtaining these specimens, or the need for
more comprehensive proteomics approaches to study low molecular weight species in tissue
[Blonder 2011]. In evaluating a tissue proteomics method for such purposes, we considered two
main capabilities; the ability to demonstrate categorical differences across tissue types and the
ability of generating sufficiently reproducible results to allow for the detection of more subtle
quantitative differences between comparison groups.
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Figure 2.8 Amino acid sequencing by collision induced fragmentation of one of the spleen peptides having an
m/z of 1179.
Mascot search results of the fragmentation spectra indicating that the molecular species at peptide m/z 1179
is a fragment of actin-2 originating from Echinococcus granulosus.
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Figure 2.9 Amino acid sequencing by collision induced fragmentation of one of the spleen peptides having an
m/z of 1213.
Mascot search results of the fragmentation spectra indicating that the molecular species at peptide m/z 1213 is a
fragment of actin cytoplasmic 2.
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Our results demonstrated that we were able to observe categorical differences between
the tissues analyzed. In terms of reproducibility, we observed that target peptide levels remained
moderately consistent across the processing and analysis steps. Additionally, data normalization
on the index peptides across 6 sheep did not significantly improve reproducibility, which
suggested that some of the variation observed was likely due to biological variability. Many
types of biological variability can occur including age, gender, feeding, immune status, breed,
the timing of sample collection, specimen storage, etc. While some of these may be hard to
control at an abattoir, most of these can be controlled or accounted for in the laboratory or
clinical setting.
Other factors are also likely to contribute to variability in any tissue proteomic approach.
One of these would be the tissue region dissected for analysis. Specifically in the sheep spleens
utilized here, while some effort was made to be consistent, the actual cellular composition of
tissue being homogenized was undoubtedly somewhat different across these multiple spleens.
For example, no attempt was made to remove fat, blood vessels or to microscopically classify
tissue. Additionally, non-biological differences such as instrument sensitivity, ionization
efficiency, variable peak suppression and other factors undoubtedly contributed to variability.
Normalization can help compensate for these non-biological sources of variability and is
especially helpful if studies occur over weeks to months. Also, once candidate biomarkers or
other species of interest are identified more quantitative methods such as heavy isotope analogue
addition to specimens can lead to absolute quantitation and marked improvements in CV.
Variability is also observed in other commonly used proteomics methods. For example,
the serum proteomics method from which we have adapted and developed this tissue proteomics
method, has a reported CV of 21.4% [Merrell 2004]. Additionally, two dimensional gel

69
electrophoresis, which is one of the most commonly used methods for tissue proteomic analysis,
not only has a low throughput and requires a large amount of clinical material for marker
discovery compared to MS based approaches [Kohn 2007, Petricoin 2003], but also has a
reported CV ranging from 12% to 70% [Comings 1972, Andersen 1997, Schroder 2008].
Thus, this tissue proteomics approach appears to fall within the same range of variability
compared with other currently used exploratory tissue proteomics methods. Because of its focus
on the lower molecular weight components of tissue, this approach will very likely provide
complementary information about tissue or cellular processes, survey many more molecular
species and hence have potential value in the study of tissue biology, particularly for the
exploration of the low molecular weight and/or lower abundance tissue proteome.
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3. Chapter 3 - Serum Biomarker Identification for Preeclampsia
Summary
Previously, we have performed a biomarker discovery study for the early prediction of
preeclampsia (PE) using maternal serum at 12 to 14 weeks of pregnancy as a discovery medium,
where the pregnancies were followed until completion to distinguish which pregnancies turned
out to be preeclamptic and which ones continued on to have normal, uncomplicated pregnancies.
The discovered markers were also submitted to different statistical analyses to determine these
markers' ability of significantly distinguishing cases of PE versus normal controls. Following our
biomarker discovery studies, we proceeded to perform identification studies to determine the
amino acid sequences or identities of the promising markers. Current findings of these
identification studies will be reported here.

Background
PE Characteristics
According to the International Society for the Study of Hypertension in Pregnancy
(ISSHP), PE is defined as hypertension that occurs after 20 weeks of pregnancy along with
proteinuria (Anderson 2012, Kue 2011). Hypertension is characterized by a systolic blood
pressure of greater than 140 mmHg and/or a diastolic blood pressure of greater than 90 mmHg
measured twice within 4 hours (Anderson 2012), while proteinuria is described as protein in
urine with concentrations greater than 300 mg per 24 hours (Anderson 2012, Ciantar 2011, Khan
2011). Furthermore, the hypertension and proteinuria are resolved postpartum (Ciantar 2011). In
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fact, at present, the only definitive cure for PE is to deliver the baby and remove the placenta
(Ramma 2011, Dennis 2012).
These two key features of PE, hypertension and proteinuria, have been known and
reported since ancient civilizations such as Egypt, China, as well as India (Ciantar 2011). In
addition to these two key features, additional factors also characterize gestational hypertension
and PE, as detailed in Table 3.1.
Hypertension in pregnancy can occur in women who already have hypertension prior to
pregnancy, or in other instances, hypertension can manifest during the second half of pregnancy
in women who weren't previously hypertensive, which is often known as pregnancy-induced
hypertension or gestational hypertension (Ciantar 2011). PE also often coexists with or causes
other pregnancy disorders such as intrauterine growth restriction (IUGR), and preterm birth
(Costa 2011, Dennis 2012).

PE Occurrence and Risks
PE is considered one of the most common pregnancy complications and the most
common hypertensive pregnancy disorder (Sibai 2003, Pennington 2012) and is known as a
potentially life-threatening condition that complicates approximately 3-8% of all pregnancies
around the world (Hagmann 2012, Bates 2011, Dennis 2012). This translates to 8.5 million
women worldwide each year (Anderson 2012). This disease is also associated with significant
mortality and morbidity rates in both the mother and the baby, estimated at more than 60,000
maternal deaths each year (Hagmann 2012) and approximately 40% of fetal mortality (Anderson
2012). Over the past several decades, there has been an increase of nearly 40% in PE occurrence,
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Table 3.1 Symptoms of Gestational Hypertension/ PE (Adapted from Publications Committee 2011)
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which is largely thought to be a result of an increase in multiple births, in the rate of maternal
obesity, as well as in the maternal age at onset of pregnancy (Roberts 2003).
The risk of PE is estimated at approximately 4.1% in women with their first pregnancy
and approximately 1.7% in consecutive pregnancies overall (Ciantar 2011). However, this risk
increased to 14.7% in the second pregnancy if the woman had PE in her first pregnancy, and
31.9% if the previous two pregnancies were preeclamptic (Hernandez-Diaz 2009). Thus,
previous PE greatly increases the likelihood of future disease occurrence (Gilbert 2012).
In addition to previous PE and hypertension as possible risk factors for the development
of future PE, several other factors include sociodemographic factors, life habits, as well as
maternal health condition. Sociodemographic factors involve characteristics such as maternal
age, marital status, education, or occupation (Forest 2012). Life habits such as smoking
cigarettes and drinking alcohol extensively have been shown to increase PE risk (Yang 2012,
Forest 2012). Maternal health prior to pregnancy has also been shown to influence the
occurrence of PE. These risk factors include medical history of chronic hypertension, diabetes,
obesity (BMI > 35), kidney disease (Uzan 2011 Glibert 2012), hyperlipidemia (Yang 2012),
fibromatosis, endometriosis, polycistic ovary syndrome (Torricelli, 2012), etc. Furthermore,
extreme maternal ages of more than 40 years old or less than 16 years old are associated with this
disease risk as well (Torricelli 2012).
It has also been found that those who have experienced PE have an increased risk of
developing various diseases later in life. These diseases include higher incidences of
hypertension, obesity, lipid and glucose metabolism disturbance, ischemic heart disease, stroke,
venous embolism, and cardiovascular diseases (CVD) later in life (Giguere 2012). In terms of
CVD, there have been several studies that suggested similarities between PE and CVD in their
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pathophysiological mechanisms, such as endothelial dysfunction, oxidative stress, and metabolic
alterations, as well as similar risk factors associated with the two diseases (Facca 2011).

Types of PE
The two main types of PE, distinguished based on when the clinical signs occur, are early
onset PE with clinical symptoms occurring before 34 weeks of pregnancy and late onset PE with
clinical manifestations occurring after 34 weeks of pregnancy (Forest 2012). It has been
proposed that early onset PE is of placental origin and is associated with abnormal spiral arteries
remodeling (Kue 2011, Sidani 2011), whereas late onset PE is of maternal origin and results
predominantly from maternal factors such as impaired glucose tolerance, obesity, high blood
pressure, or dyslipidemia (Kue 2011).
Some clinical manifestations of early onset PE include placental dysfunction, placental
volume reduction, intrauterine growth restriction (IUGR), abnormal uterine and umbilical artery
Doppler measurement, low birth weight, perinatal death, multi-organ dysfunction as well as
other adverse maternal and neonatal outcomes (Raymon 2011). On the other hand, because late
onset PE is thought to be of maternal origin, perinatal outcomes are generally more favorable
(Costa 2011) with normal placenta and fetal growth, normal uterine and umbilical artery Doppler
measurement, birth weight, and more favorable neonatal and maternal outcomes (Raymon 2011).
Another PE distinction is based on the severity of symptoms, namely mild and severe PE.
The characteristics of PE used by the International Society for the Study of Hypertension in
Pregnancy (ISSHP) and discussed earlier in this chapter, reflect blood pressure and proteinuria
measurements used to diagnose mild PE. However, severe PE is diagnosed when more severe
elevations of blood pressure (systolic > 160 mmHg, and diastolic > 110 mmHg) are observed or
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if there is evidence of other organ dysfunction (Pennington 2012, Dennis 2012). Severe PE may
also include central nervous system (CNS) problems, such as headaches, seizures (eclampsia),
impaired consciousness, visual disruption, renal dysfunction, hematological complications, as
well as uteroplacental compromise (Dennis 2012).

Current PE Pathogenesis Theories
PE has been referred to as a disease of theories due to the lack of knowledge regarding its
actually etiology (Dekker 1998). Some theories that have been proposed include angiogenic
imbalance and excessive inflammation (Ramma 2011). In the angiogenic theory, it is proposed
that in PE there is an imbalance between proangiogenic factors such as vascular endothelial
growth factor (VEGF) and placental growth factor (P1GF) and antiangiogenic factors such as
soluble endoglin (Eng) and soluble VEGF receptor 1 (sFlt-1) (Laresgoiti-Servitje 2012).
Recently, further evidence of excessive inflammation has been shown to be present in PE
in the presence of higher activation of the complement system compared to normal pregnancies,
which increases the levels of inflammation (Ramma 2011). However, several studies have failed
to find a strong and consistent association between excessive inflammation level and the clinical
signs observed in PE, which weakens this theory (Ramma 2011). It has been recently proposed
that inflammation may be a result of PE rather than the cause of it (Ramma 2011).
Placental oxidative stress has also been proposed to play an important role in PE
causation (Salles 2012). Oxidative stress is described as an imbalance between pro-oxidant and
antioxidant protection that has been reported in maternal circulation and placenta in PE (Yang
2012). Unfortunately, the presence of oxidative stress is also observed in normal pregnancies,
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since pregnancy itself is considered a condition of increased oxidative stress susceptibility as
seen in sharp rises in the oxygen tension during early gestation (Yang 2012, Jauniaux 2000).
Other researchers also suggest two common PE theories, which involve genetic and
immunologic origins (Uzan 2011). The genetic theory was proposed due to observations that
women with family history of PE have 2 to 5 fold increased susceptibility to PE (Sidani 2011).
Another genetic-associated observation has shown that spouses of men who were preeclamptic
babies are also more likely to experience PE (Sidani 2011). As for the immunologic theory, in
normal pregnancies the mother's immune system experiences significant changes to
accommodate fetal survival and it is thought that in PE these changes are exaggerated (Raymon
2011). It has also been shown that an immunological imbalance leads to placental failure, which
can be associated with PE (Ciantar 2011).
However, because of the multiple theories associated with PE, several researchers have
proposed the multifactorial nature of this disease (Sidani 2011). Thus, it is conceivable that PE is
a result of the convergence of several different pathophysiological pathways (Costa 2011).

PE Prevention and Early Detection
Studies have shown several factors that are protective towards PE, such as physical
activity, which has been shown to reduce or minimize the likelihood of having PE (Forest 2012,
Kasawara 2012). Another possible means of prevention that has been reported is the use of low
dose aspirin to reduce the risk of PE (Smith 2012). The use of aspirin has been found to reduce
PE risk by 17%, and this risk reduction is found to be even higher (25%) in high risk women
(Ciantar 2011). Other studies have shown that aspirin treatment should be initiated early in the
pregnancy (before 12-14 weeks of pregnancy) in order to achieve maximum PE risk reduction
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(Uzan 2011). However, several very large clinical trials of low dose aspirin initiated early in
pregnancy and maintained until delivery failed to show any benefit.
In response to the placental oxidative stress theory, several groups have suggested the
potential use of anti-oxidants to reduce PE rates. As a result, several large double-blind, placebocontrolled clinical trials of anti-oxidant vitamins have been carried out but none showed a
reduction in the rate of PE.

Current PE Biomarkers
Despite the uncertainty of the cause of PE, most clinicians are nonetheless interested in
having biomarker tests that clearly define women at high risk of PE to allow them to
appropriately manage their pregnancies. Several PE biomarkers have been proposed in the past,
including physical parameter types of biomarkers as well as biochemical types of markers.
Physical parameters such as Doppler ultrasound evaluations or mean arterial blood pressure
(MAP) have been used as indicators for PE (Huppertz 2012). Because PE is thought to be a
consequence of abnormal placental invasion, it is conceivable that using uterine artery Doppler
(Ut-AD) measurements of blood flow through fetal and uteroplacental circulation can provide
meaningful diagnostic information (Mace 2012). Ut-AD measurements alone have been reported
to have a detection rate of 63% and 25% false positive results in the detection of PE (Mace
2012). Ut-AD typically provides the best screening efficacy when used in the second trimester
(between 24 and 26 weeks of gestation) (Torricelli 2012, Pedrosa 2011). However, it is not a
simple test and those less acquainted with the technique often obtain misleading results.
Ideal PE biochemical markers should follow specific characteristics, such as comprises
factors that play a key role in PE pathogenesis, appear before clinical manifestation of disease,
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be easy and cheap to measure, have high sensitivity and specificity, correlate with disease
severity, and not be expressed or detected in normal pregnancies (Anderson 2012). While it
continues to be challenging to obtain biochemical markers that fulfill all these criteria, several
categories of biomarkers have been studied in the recent years, as outlined in Table 3.2 below.
Some of the biomarkers listed in Table 3.2 are placental factors, such as pregnancyassociated placental protein A (PAPP-A) and placental protein 13 (PP-13). It has been shown
that low maternal serum PAPP-A and PP-13 are associated with an increased likelihood of
developing PE (Costa 2011) when screened in the first trimester of pregnancy (Anderson 2012).
Additionally, some other potential markers also reported in Table 3.2 are angiogenic
factors such as soluble fms-like tyrosine kinase-1 (sFlt-1), P1GF, and soluble endoglin (sENG).
The angiogenic factor imbalance in PE are associated with anti-angiogenic factors such as (sFlt1)
and sENG being upregulated, which lead to the observation of reduced circulating angiogenic
factors such as P1GF (Forest 2012). Furthermore, this angiogenic imbalance also correlates with
PE symptom severity (Hagmann 2012).
One possible marker combination for PE diagnosis in the second trimester is the ratio of
P1GF and sFlt-1. Several studies have indicated that P1GF/sFlt-1 ratio can predict 89% of PE
incidence (De Vivo 2008). Additionally, alterations in their levels occur at around 6 weeks
before onset of symptoms and correlate to disease severity (Anderson 2012).
Other combinations of markers have also been considered, and generally such
combinations have better predictive values than single markers alone. Considering combinations
of markers is of value particularly because PE is considered to be a multifactorial disease, and
therefore, combinations of several potential predictors that reflect various causes or aspects of
the disease may potentially provide stronger prediction of PE (Costa 2011). For instance,
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Table 3.2 Summary of Potential Biomarkers for PE Detection in Maternal Blood (adapted from Costa 2011)
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combining uterine artery Doppler measurements with biochemical markers may provide
increased predictive values for the risk of PE (Hui 2012).
Despite initial studies of several promising markers for PE risk assessment, in unselected
pregnant women, none of these biomarkers have been approved and none shown to be useful in
predicting PE. At present there is a significant need for reliable clinical tests that can provide
early prediction of mothers at high risk of PE before manifestation of clinical symptoms (Kue
2011). My research is focused on the discovery and identification of more reliable clinical
markers for the early prediction of PE. Our hypothesis was that a serum proteomic approach we
had developed that interrogates the lower MW proteome would provide such predictive PE
biomarkers.

Our PE Biomarker Discovery Study
Previous biomarker discovery studies in our lab were performed using 55 protein
depleted pregnancy serum taken at 12-14 weeks of pregnancy from pregnant women followed to
the completion of the pregnancy. Of the 55 serum specimens, 27 originated from normal
uncomplicated pregnancies and 28 serum specimens originated from women who developed
later PE after weeks. Many potential biomarkers of interest were observed in this sample set and
many showed statistical differences between cases and controls in their abundance (p < 0.05).
Markers with p-values of less than 0.1 were also considered for possible combined panels of
markers that increased predictive values. In this initial PE biomarker discovery study, 29 markers
were found to have a p-value < 0.05 and 66 markers with p-value < 0.1. Many of these markers
were then submitted to fragmentation experiments to determine the amino acid sequence or
chemical identity of these markers, and the results are reported here.
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Methods
Sample Preparation
LC/MS runs from the initial biomarker discovery stage or from recently ran serum
specimens were carefully analyzed to determine which specimen contained a good amount of the
specific biomarker to be sequenced. An aliquot of these previously acetonitrile precipitated
specimens from maternal pregnant serum (either serum from mothers who proceeded to have
normal pregnancies or PE) were prepared, containing 0.5 µg of apparent protein content as
determined using a Bio-Rad microtiter plate protein Assay (Bio-Rad Laboratories, Hercules,
CA). This aliquot was acidified using 2.5 µL of 88% formic acid prior to injection to the mass
spectrometer. All specimens used for the fragmentation studies were hand injected rather than
injected through the autosampler to conserve specimens.

Initial Pre-fragmentation cLC-MS Run
Prior to performing fragmentation experiments, specimen containing the molecule of
interest was submitted to two cLC-MS runs. The purpose of these two initial cLC-MS runs was
to determine the exact elution time of the molecule of interest. As a general rule, we required that
the two elution times from the two runs for the molecule of interest be within half a minute of
each other. If, however, in the second run the molecule of interest eluted more than 30 sec apart,
a third cLC-MS run was performed, and generally this third run yielded a satisfactorily
consistent elution time for the peptide of interest.
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Peak elution times may vary due to various reasons such as ambient temperature of the
room where the instrument is located, instrument day-to-day performance, etc. In our sequencing
experiments, it was important to establish consistent elution times for the peptide of interest
because when performing the LC-MS/MS method a two-minute window was specified blindly
where fragmentation data was gathered. Thus, in order to obtain fragmentation of the correct
molecule, this two minute-window needed to coincide for the molecule of interest consistently.
The initial cLC-MS runs were performed using a 1 mm (16.2 μL) microbore guard
column (Upchurch Scientific, Oak Harbor, WA) and a 15 cm x 250 μm i.d. capillary column
assembled in-house. POROS R1 reversed-phase media (Applied Biosystems, Framingham, MA)
was used to dry-pack the guard column and slurry pack the capillary column. The aqueous phase
used was 98% HPLC grade H2O, 2% acetonitrile, 0.1% formic acid and the organic phase was
2% H2O, 98% acetonitrile, 0.1% formic acid.
In our regular cLC-MS runs used for biomarker discovery, a typical elution gradient
lasted for approximately 55 minutes. However, in these pre-fragmentation initial cLC-MS runs,
we utilized a shorter gradient of 40 min where the first half of the gradient was identical to the
longer gradient because the majority of peaks of interest eluted in this first half of the gradient.
The latter half of the gradient was shortened to speed up the runs.
The elution started with 3 min of 95% aqueous phase and 5% organic phase, followed by
a linear increase to 60% organic phase over 20 min. The gradient was then further increased to
95% organic phase over 5 min and held at 95% organic for 6 min. The gradient was then
returned to 95% aqueous phase over 3 min and held there for 3 more minutes to re-equilibrate
the column. The flow rate was kept at 5.0 μL/min.
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The cLC system coupled to our mass spectrometer was a LC Packings Ultimate Capillary
HPLC pump system. This cLC system was coupled to a QSTAR Pulsar I quadrupole orthogonal
time-of-flight mass spectrometer through an IonSpray source (Applied Biosystems) with a
voltage of 4800V. The cLC-MS data were collected for m/z 500 to 2500 with mass spectra
obtained every 1 sec. All the experiments reported here were performed in positive ion mode.
The elution profile of the cLC fractionated sample of each sample was reported as the total ion
chromatogram and the Analyst QS® 1.1 software (Applied Biosystems, Foster City, CA) was
used to visualize and analyze the data.

Sequencing of Molecules of Interest with a QSTAR Pulsar I Quadrupole Orthogonal Timeof-Flight Mass Spectrometer
Once a consistent elution time had been established for the molecule of interest, another
aliquot containing 0.5 µg apparent protein was prepared and acidified with 2.5 µL of 88% formic
acid and submitted to MS/MS analysis. The specimen was hand injected and MS/MS
fragmentation data were collected from m/z 50 to a maximum m/z value higher than the mass of
the parent molecule of interest. MS/MS data were gathered during the relevant elution interval
which was set to be 2 min in duration. In many cases N2 was used as the collision gas. However,
when more fragments were desired, we also used argon as a collision gas. Multiple runs, each of
different collision energy, were used to obtain a good coverage of fragments of the molecule of
interest. The determination of which collision energy was to be used in subsequent fragmentation
of the same molecule of interest was dependent upon the size of the molecule of interest and the
fragments produced in the previous run. For example, generally, larger proteins required higher
collision energies to obtain more fragments because larger proteins are likely to have more
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complex tertiary structure that require higher collision energies to dissociate. Additionally, if
more larger fragments were desired (those appearing later in the m/z range of the spectrum)
collision energies were decreased, and if more smaller fragments were desired (those appearing
in the earlier m/z range of the spectrum) then higher collision energies were used.
Once all the MS/MS runs were completed for a given molecule, spectra from all the
collision energies were overlaid and summed into a single MS/MS spectrum consisting of good
fragmentation coverage. The summed spectrum was visually inspected and compared to the
exported peak lists to check for any miss-assigned charge states. In general, charge states were
more likely to be miss-assigned when the molecules or fragments were of higher charge states
(greater than +2 or +3).
Once all the charge states had been corrected, all the peaks in the data list were
transformed into their +1 m/z values using the formula: +1 mass = m/z value * charge – (charge
– 1H+) to simplify the database search. The corrected mass list was exported as a tab-delimited
text file and submitted to Mascot (Mascot 2.3, www.matrixscience.com) database search. The
parameters used for Mascot searches were no enzyme digestion, SwissProt database, no
modifications, peptide tolerance of 1.2 Da, and MS/MS tolerance of 0.6 Da. Additionally, the
Mascot search results were often cross-checked against a protein Blast search
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) or other databases to confirm the results.

Statistical Analysis of Biomarkers of Interest and Determination of Biomarker Panels
The 66 PE biomarkers with a p-value of <0.1 were sent to a biostatistician for further
statistical analyses. These analyses involved calculations of single marker area under the curve
(AUC) as well as determinations of combinations or panels of biomarkers with AUCs greater
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than 0.8. A Pearson correlation was calculated, and a logistic regression as well as the area under
the receiver operating characteristic curve were used to measure the predictive value of each
individual marker, as reported by their single marker AUC (Sing 2009).
In the development of biomarker combination panels, a forward selection logistic
regression approach was used. This approach was initiated by the selection of one biomarker
molecule, then additional molecules were added one by one to the model prioritizing markers
that yield the highest increase in AUC. Addition of molecules to the model was stopped when
such additions did not further increase the AUC of the combination. Of the many marker
combinations obtained using this approach, three models which consisted of markers with known
identities are reported here.
Additionally, the frequency of individual markers being part of multi marker panels was
determined and this was used to establish markers for the fragmentation studies. For instance,
markers that occur in several biomarker panels were considered more important than those that
appeared in one or two.

De Novo Sequencing of Protein or Peptide Markers
There were occasions when Mascot database searches of peptide marker MS/MS spectra
did not yield any promising results. In these instances de novo sequencing of these markers was
attempted. To do this, MS/MS spectra were first examined for b1 and/or y1 ions which indicate
the start of the peptide sequence at either the N- or C-terminus. These ions were present in the
lower m/z ranges of the spectra. Once an end of the sequence (either b1 or y1) was identified,
m/z differences from these end ions to the following peaks in the spectra were calculated, and the
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m/z differences were compared to masses of the 20 different amino acids. This process was
continued until a chain of amino acid sequence was determined.
In an ideal study, the fragmentation coverage was such that complete amino acid
sequences were obtained from the end ion all the way up to the parent m/z (Figure 3.1).
However, often this was not the case. Even when complete coverage was not obtained, as a
general rule, if a sequence of at least 5 or 6 consecutive amino acids was obtained through de
novo sequencing, this sequence was submitted to a Blast search
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to determine the parent protein identity.
There were other occasions where an end ion could not be detected. In these situations,
one can arbitrarily start on a peak with a good intensity and proceed to determine m/z differences
to the following peaks to find any possible amino acid sequence chain from the spectra. Again, a
5 to 6 amino acid sequence can then be submitted to a Blast search for possible identification.
However, it is also important to keep in mind that when a sequence does not start on an end ion,
there was no information regarding directionality of the sequence. Thus, when performing a
Blast search in this situation, it is necessary to submit the amino acid sequence ordered in both
directions to the search engine.

Manual Identity Determination of Lipid Markers
In addition to protein or peptide biomarkers, we have also recently discovered that
several of the potential biochemical markers discovered in our initial PE set were lipids,
specifically belonging to the class of glycerophosphocholines. To illustrate a de novo approach
to such a molecule, we will use the candidate m/z 756.5 as an example. The possibility of nonpeptidic markers was first considered when MS/MS fragmentation of several potential markers

87

Figure 3.1 Example of MS/MS fragmentation spectra with a good fragmentation coverage
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yielded apparently "poor" fragmentation that didn't provide the good fragmentation coverage we
usually observed in peptide MS/MS spectra even when multiple collision energies were used
(Figure 3.2).
As observed in Figure 3.2, fragmentation of peak m/z 756.5, regardless of the use of
several collision energies, yielded only 2 very prominent peaks, the parent compound at m/z
756.5 and an even more prominent peak at m/z 184.07. The fragment ion at m/z 184.07 is known
to reflect the presence of the phosphocholine head-group (Figure 3.3) (Brown 2009, Byrdwell
2005). Therefore, in our subsequent MS/MS experiments for other molecules, the presence of
this very abundant fragment ion at m/z 184.07 was used as the primary indicator that the markers
of interest were glycerophosphocholine molecules.
Because several of these non-peptide markers provided statistically significant
distinctions between PE cases and non-PE controls, there was significant interest in attempting to
determine the identity of these markers. In order to do so, an initial search was performed on the
LIPID MAPS database (http://www.lipidmaps.org/) by submitting the parent mass of the neutral
form to the search engine. An example of the LIPID MAPS search of the molecule at m/z 756.5
is shown in Figure 3.4. In the initial search, there were more than 50 matches obtained for
various molecules. However, in Figure 3.4 below we included only the 11 search matches for the
glycerosphocholine (PC) molecules because of the presence of m/z 184.07 in our MS/MS spectra
clearly indicates that the molecule of interest is a PC. As seen in Figure 3.4, even when the
results were narrowed down to only phosphocholines, multiple results were still obtained from
this initial search. This was mainly due to various possibilities in chain lengths of the two fatty
acyl groups of the glycerophosphocholine molecules, as well as double bond position (if present)
within each chain.
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Figure 3.2 Example of an MS/MS fragmentation with "poor" fragmentation coverage
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Figure 3.3 Six major classes of glycerohospholipid (adapted from Brown 2009).
The red box highlights the glycerophosphocholine headgroup, which gives a very prominent fragment ion at m/z
184.07.
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Figure 3.4 LIPID MAPS search results for molecule m/z 756.5 showing the phosphocholine matches
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In an attempt to narrow down the search results, we used the LIPID MAPS MS prediction
tool (http://www.lipidmaps.org/tools/index.html). To use this software, the parent mass was
input, as well as sn1 and sn2 acyl chain information, and the software generated the predicted
fragments reflecting the m/z for sn1- and sn2-acyl loss in MS/MS experiments (Figure 3.5).
These m/z values were then compared with the MS/MS fragmentation spectra to determine the
presence of these fragments, which would indicate our marker of interest was that specific PC
molecules.
Chain length/double bond information from the initial LIPID MAPS search was added
into the lipid maps MS prediction tool. For example in Figure 3.5 an sn1 chain of 16:1 and an
sn2 chain of 18:2 were input (one of the possible lipid maps matches for the molecule of
interest), and the fragments with acyl loss obtained were m/z 520.3 and 494.3.
Every search match from LIPID MAPS general search was input into the LIPID MAPS
MS prediction tool and the calculated acyl losses were recorded for each search result with
comparison to the actual MS/MS spectra. The possible molecules from the LIPID MAPS search
whose calculated sn1 and/or sn2 loss weren't present in the MS/MS spectra were eliminated as a
candidate. Although the initial MS/MS spectra appeared to only have 2 prominent peaks (parent
compound and PC head group), amplifying the spectra revealed additional lower abundance
fragments that could be compared to the calculated acyl losses obtained from the prediction tool
(Figure 3.6).
As seen in the Figure 3.6, the fragment peaks at m/z 494.3 and 520.3 were present in
observable amounts when the MS/MS spectrum was enlarged. These two peaks represent acyl
loss m/z's for PC (16:1/18:2) based on the calculations obtained from the LIPID MAPS MS
prediction tool. Additionally, upon inspection of the calculated acyl loss m/z's for the other
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Figure 3.5 LIPID MAPS MS prediction tool search criteria for the prediction of sn1- and sn2- acyl loss of
molecule m/z 756.5.
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Figure 3.6 MS/MS spectra revealing fragment ions of molecule m/z 756.5 (zoomed in view to better visualize
the lower abundance fragment ions).
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possible PC molecules, it was concluded that none of the other possible PC molecules gave rise
to acyl loss m/z's that were present in the MS/MS spectra. This suggested that PC (16:1/18:2)
was the most likely parent molecule for our peak of interest.
However, in order to confirm this possible match, identification of additional fragments
was desirable. To do this, we referred to information regarding previously reported MS/MS
fragments of glycerophosphocholine (Figure 3.7) (Byrdwell 2005).
Figure 3.7 outlines the possible fragments of glycerophosphocholine when subjected to
MS/MS analysis. To further confirm whether or not the molecule m/z 756.5 was indeed PC
(16:1/18:2), the molecular structure of PC (16:1/18:2) was manually drawn as well as its
predicted fragments based on the guidelines outlined in Figure 3.7 (Byrdwell 2005). The m/z's of
these predicted fragments were manually calculated and recorded (Figure 3.8) and compared to
the actual MS/MS spectra.
Note that the fragments marked with a check mark at the bottom in Figure 3.8
represented fragments whose calculated m/z values appeared in observable amounts in the
MS/MS spectra of molecule m/z 756.5 (Figure 3.9). Figure 3.9 below represented a scaled
version of the same MS/MS spectra for the fragmentation of molecule m/z 756.5 as shown in
Figure 3.2, with the matched fragment ions labeled.
In addition to the predicted fragments of glycerophosphocholine as outlined by
Byrdwell 2005, additional fragment ions are also labeled in Figure 3.9, which are parts of the
phosphocholine head group. One of these ions included molecule m/z 124.9, which is the
phosphocholine head group where the choline portion is not part of the fragment molecule.
Another additional fragment ion labeled in Figure 3.9 is molecule m/z 86.09, which is the head
group without the phosphate portion.
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Figure 3.7 Predicted fragments of phosphocholine molecules (adapted from Byrdwell 2005).
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Figure 3.8 Predicted fragment ions for MS/MS of PC (16:1/18:2)
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Figure 3.9 MS/MS spectra of molecule m/z 756.5 zoomed in for better visualization of fragment ions.
Predicted fragments of m/z 756.5, as calculated and reported in figure 3.8, were labeled here.
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In Figure 3.9 we can see that although present in much smaller amounts compared to the
PC head group (m/z 184.07), the matched fragments that are labeled in the MS/MS spectrum
appear to be readily detectable and substantially above background in the spectrum. Furthermore,
additional fragments representing the phosphocholine head group were confirmed to be present
in the MS/MS spectra. Taken together, all this provides confirmation that the molecule PC
(16:1/18:2) is indeed our molecule of interest.

Results
PE Biomarkers Results Overview
Of the 66 PE biomarkers with a p-value of < 0.1, MS/MS fragmentation experiments
were attempted on 35 markers, selected based on AUC values as well as the frequency of their
occurrence in multiple marker models. Many of these 35 molecules only yielded partial sequence
or identity information. Of these 35 fragmentations, 19 molecules have been classified as to
compound type (peptide, glycerophosphocholine). However, due to issues such as poor
fragmentation coverage, the appearance of non-peptide-like or non-glycerophosphocholine-like
fragmentation pattern, low levels of parent compound, and the lack of additional specimen
containing these markers of interest, the exact amino acid sequence or chemical structure has
only been accomplished for 8 of these molecules (Table 3.3). These 8 molecules consist of 5
peptides and 3 glycerophosphocholine compounds.
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Table 3.3 Amino Acid Sequence or Chemical Structure for 8 PE Candidate Biomarkers
m/z

charge

MW

942.6

1

941.5

1238.5

1

1237.5

1070.8

4

676.7

sequence/structure

parent protein/compound

hwesasll

Complement C3

4279.25

pyro-egvndneegff
nvhsagaagsrmnfrpgvlss
rqlglpgppdvpdhaayhpf

3

2026.98

qlglpgppdvpdhaayhpf

1014.5

2

2026.98

qlglpgppdvpdhaayhpf

756.6

1

755.6

PC(18:2/16:1)

508.3

1

507.3

PC(O-18:1)

594.3

1

593.3

PC(16:0/5:0(CHO))

Beta-fibrinogen
Inter-alpha-trypsin inhibitor heavy
chain H4 isoform 2
Inter-alpha-trypsin inhibitor heavy
chain H4 isoform 2
Inter-alpha-trypsin inhibitor heavy
chain H4 isoform 2
1-(9Z,12Z-octadecadienoyl)-2-(9Zhexadecenoyl)- glycero-3phosphocholine
1-(11Z-octadecenyl)-sn-glycero-3phosphocholine
1-hexadecanoyl-2-(5-oxovaleroyl)-snglycero-3- phosphocholine
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Identified PE Peptide Biomarkers
Of the 5 identified peptides, 2 were identified via Mascot search, peptides m/z 942.6 and
1070.8 (Figures 3.10 and 3.11). The Student's T-test calculations revealed that peptide m/z 942.6,
a fragment of complement C3, was higher in the serum of women with normal pregnancies. The
p-value for peptide m/z 942.6 was 0.017, with a single marker AUC of 0.611. Conversely,
peptide m/z 1070.8 which is a fragment of inter-alpha-trypsin inhibitor heavy chain H4 isoform
2, was shown to be higher in PE. Additionally, the p-value for peptide m/z 1070.8 was 0.087 and
its single marker AUC was 0.242.
The third and fourth peptide biomarker, peptides m/z 676.7 and 1014.5, were identical
fragments of the same protein with different charge states, where 676.7 is the charge +3 form and
1014.5 is the charge +2 form. This marker was previously identified as being a marker for our
preterm birth study that has been previously published (Esplin 2011). Interestingly, in our
previously published preterm birth study, peptide m/z 676.7 was found to be much higher in
normal uncomplicated pregnancies, while it's presence was substantially lower in preterm birth
cases. However, in our PE study, this peptide was found to be in higher amounts in cases of PEs,
with a p-value of 0.1339 and a single marker AUC of 0.477.
The last peptide biomarker, peptide m/z 1238.5, was identified via de novo sequencing
(Figure 3.12). The MS/MS fragmentation spectra for this peptide did not provide a good Mascot
match, which was likely due to a modification in the amino acid sequence. This peptide was
identified as being a fragment of β-fibrinogen with a pyroglutamic acid modification on its Nterminus in place of a glutamine (Q). This marker had a p-value of 0.032, with a single marker
AUC of 0.562. Additionally, peptide m/z 1238.5 was found to be higher in normal, nonpreeclamptic pregnancies.
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Figure 3.10 Mascot search match for peptide m/z 942.5 indicating that this peptide is a fragment of
complement C3 protein.
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Figure 3.11 Mascot search match for peptide m/z 1070.8 indicating that this peptide is a fragment of interalpha-trypsin inhibitor heavy chain H4 isoform 2.
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Figure 3.12 MS/MS fragmentation spectra for peptide m/z 1238.5 with the amino acid sequence obtained
from de novo sequencing labeled.
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PE Glycerophosphocholine Biomarkers
Although several of the 36 fragmented biomarkers of interest have been categorized as
being a glycerophosphocholine based on the presence of a very highly abundant fragment ion at
m/z 184.07, we were only able to determine the exact molecular identity of 3 of these
phosphocholine molecules (Table 3.3). The first phosphocholine molecule, m/z 756.5 (Figure
3.9) was identified as being PC (16:1/18:2), following the identification steps outlined in the
Methods section. This marker had a p-value of 0.018 and a single marker AUC of 0.613.
Additionally, this marker was shown to be higher in non-preeclamptic pregnancies.
The second phosphocholine biomarker, m/z 508.3, was identified as being lyso-PC(O18:1) (Figure 3.13) following the same steps outlined in the Methods section. The p-value for
this marker was 0.0002 and the single marker AUC was 0.748. This marker was much higher in
normal pregnancies. The last phosphocholine marker identified following the above mentioned
steps, m/z 594.3, was found to be PC(16:0/5:0(CHO)) (Figure 3.14). This marker was found to
be present in higher amounts in PE pregnancies with a p-value of 0.023, with a single marker
AUC of 0.589.

Biomarker Panel Development
As can be seen in the data reported above, no single identified marker had an AUC
greater than 0.8, which is the generally accepted standard for clinical test purposes. Therefore,
further statistical analyses were performed on 55 the potential biomarkers to determine possible
marker combinations with better predictive value. These statistical analyses yielded three panels
of 3 to 4 biomarkers with an AUC of greater than 0.8 (Table 3.4).
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Figure 3.13 MS/MS fragmentation spectra of molecule m/z 508.3 with the predicted fragments labeled.
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Figure 3.14 MS/MS fragmentation spectra of molecule m/z 594.3 with the predicted fragments labeled.
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Table 3.4 Several Good Candidate Biomarker Combination Models for PE Prediction
Markers
508.3, 594.3, 756.5
508.3, 594.3, 942.6
508.3, 594.3, 942.6, 1014.5

AUC
0.832
0.812
0.810
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The best biomarker panel that relied only on our identified PE markers is a panel of markers m/z
508.3, 594.3, and 756.5 which gave a combined AUC of 0.832 (Figure 3.15). This panel gave a
sensitivity of 57% and a specificity of 100% (or ~88% sensitivity at a specificity of ~70%) in
distinguishing normal pregnancies from pregnancies complicated by PE.
The second best biomarker panel using our identified markers was a panel consisting of
markers 508.3, 594.3, and 942.6, which gave a combined AUC of 0.8125 (Figure 3.16). This
panel was able to distinguish PE from control pregnancies with a sensitivity of 67% and a
specificity of 79%.
The third panel was a slight modification of the second biomarker panel, with the
addition of peptide m/z 1014.5, the +2 charge state of peptide m/z 676.7. This marker is reported
as 1015 in the Figure 3.17. Although the addition of peptide m/z 1015 did not improve the
combined AUC of the panel, this panel was included in this report due to its combined AUC of
greater than 0.8. This panel yielded 80% specificity and 70% sensitivity in detecting PE
pregnancies from normal control pregnancies.

Discussion
Of the 66 biomarkers considered in our initial PE biomarker discovery, we performed MS/MS on
35, and of these 35 we were only able to gain complete amino acid sequence or chemical identity
for 8 biomarkers. Despite the lack of complete identification of all the markers of interest, we
were still able to obtain promising results, with several marker combinations yielding a
combined AUC of greater than 0.8. In fact, many previous studies have suggested the value of
using panels of biomarkers, typically consisting of 3 to 5 biomarkers which have been shown to
have performance advantages (Rifai 2006).
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Figure 3.15 ROC plot and predicted probability for the biomarker panel consisting of marker m/z 508.3,
594.3, and 756.5.
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Figure 3.16 ROC plot and predicted probability for the biomarker panel consisting of marker m/z 508.3,
594.3, and 942.6.
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Figure 3.17 ROC plot and predicted probability for the biomarker panel consisting of marker m/z 508.3,
594.3, and 942.6, and 1014.5.
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In our best biomarker panel, consisting of candidates m/z 508.3, 594.3, and 756.5, we
were able to obtain a combined AUC of 0.832, with a sensitivity of 57% and a specificity of
100%. The sensitivity percentage refers to the ability of the biomarker or biomarker panel to
identify affected PE patients correctly, while specificity refers to the ability to identify unaffected
persons correctly (Kohn 2007). In addition to the good AUC obtained from our three panels
reported here, another valuable aspect of our biomarker study for PE is the fact that our
specimens were obtained early in pregnancy (12 to 14 weeks), and our markers were able to
distinguish pregnancies that developed PE many weeks later, versus those that continued to have
normal pregnancies.
Previous studies have supported the association of complement factors, fibrinogen, and
glycerophosphocholines with PE. First, in the inflammation model of PE pathogenesis, there
appears to be an association between the complement system and inflammation in PE (Ramma
2011). Second, PE has also been associated with activation of coagulation as a result of
immunologically mediated endothelial damage (Facca 2011), which may help explain the
presence of β-fibrinogen as one of our peptide markers. Lastly, in a recent study to examine the
plasma lipid profile of women with PE, many classes of lipids were found to be altered,
including glycerophosphocholines (De Oliveira 2012), which provides additional support in the
phosphocholine markers we discovered in our study set. Although it is unclear whether or not
these PC molecules mediate PE disease development, it appears that these markers could be
indicative of disease.
In our PE study, we hypothesized that using our serum proteomics approach we would be
able to observe statistically significant differences between PE and control pregnancies. Our
results not only suggested that such differences were clearly observed in the specimen set used,
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but we were also able to determine sequence information or chemical identity for several
markers as well as to develop panels of biomarkers with improved sensitivity and specificity in
PE prediction. It is also important to note that in addition to the PE biomarker panels reported
here, panels of yet to be identified PE biomarkers provided sensitivities and specificities greater
than 90%.
Regardless of good combined AUC in our biomarker panels and possible reasoning for
the presence of these biomarkers in PE studies, validation of results is still necessary to confirm
findings. In the field of biomarker studies, it is expected that not all potential biomarkers will be
able to hold up as biomarkers in validation studies and turn out to be of clinical use (Veenstra
2005). Thus, validation of our current biomarkers is crucial in order to isolate markers that are
good, reliable, and consistent risk predictors of PE across multiple specimen sets that can be
applied in the clinical setting. This validation will involve obtaining an additional specimen set
having at least the same number of samples as our initial specimen set, where we are blinded as
to the case and control status and the results will be submitted to an independent biostatistician.
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4. Chapter 4 - Serum Biomarker Discovery and Identification for Endometriosis
Summary
The purpose of our endometriosis study was to discover potential candidate serum
biomarkers for noninvasive diagnosis of endometriosis. Serum specimens were obtained from
women with a complaint of pelvic pain but absence of endometriosis and compared to serum
samples from women who have different stages of endometriosis. Serum specimens were protein
depleted to eliminate the large and highly abundant proteins and to isolate the low molecular
weight species that could be potential indicators of disease. In our studies, many markers were
discovered that yielded statistically significant differences between cases and controls.
Development of biomarker panels were also carried out to find models with high sensitivity and
specificity for endometriosis diagnosis and four biomarker panels are reported, which consisted
of markers with known identities. Furthermore, several of the markers have also been subjected
to MS/MS fragmentation experiments to determine their amino acid sequence or compound
identity and chemical identities of 6 biomarker molecules have been determined.

Background
Definition and Symptoms
Endometriosis is defined by the presence of estrogen-sensitive endometrial-like tissue
outside of the uterus (Falcone 2011, Guidice 2010). It is considered an estrogen-dependent
gynecological disease (Huhtinen 2012), with the common implantation sites being the pelvic
peritoneum, ovaries, rectovaginal septum, and uterine ligaments (Guidice 2010, Maruyama
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2012). These common pathologic implantation sites are briefly illustrated in Figure 4.1. Some
rare implantation sites include the intestines, bladder, cervix, pelvic lymph nodes, vagina, and
fallopian tubes, as well as distant sites such as the kidneys, lung, skin, brain, or even spinal
column (Giudice 2004). Endometriosis has also been shown to be the major cause of
hysterectomy in the US (Burney 2012).
Some common symptoms of endometriosis include infertility as well as severe pain due
to dysmenorrhea, dyspareunia, etc (Fritzer 2012, May 2010). However, depending on
implantation sites, additional symptoms may be present such as digestive disorders, among
others (Fritzer 2012). A suggested explanation of pelvic pain in endometriosis is based on the
fact that endometriosis lesions or implants respond to ovarian steroids in a menstrual cycle,
where it undergoes proliferation, differentiation as well as tissue break down following the
menstrual cycle (Laschke 2011). This has been suggested to cause local inflammatory reactions
in extrauterine locations that may cause the pain commonly experienced in endometriosis
(Fritzer 2012). A summary of several common endometriosis symptoms are outlined in Table 4.1
(adapted from Sinaii 2008).
In addition to gross symptoms reported by women or detected at physical exam, as
outlined in Table 4.1, several psychosocial symptoms have also been observed in patients who
have endometriosis. For instance, it has been shown that the majority of endometriosis patients
not only have to cope with physiological symptoms, but also have a strongly reduced quality of
life as well as psychosocial and psychological problems (Fritzer 2012). In many instances, this is
due to the severe pain experienced by these patients, which impairs their overall work
productivity (Fritzer 2012). Examples of the effect of endometriosis on work productivity
include the loss of an average of 10.8 hours per week due to impaired physical well-being in one
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Figure 4.1 Common endometriosis implantation sites in the pelvic cavity (taken from Brosens 2012).
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Table 4.1 Symptoms of Endometriosis (Adapted from Sinaii 2008)
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study (Nnoaham 2011), or a median absence from work at 17.8 days per year due to
endometriosis associated pain as reported elsewhere (Leeners 2007).

Occurrence and Risk Factors
Endometriosis has been shown to affect approximately 6 to 10% of women who are of
reproductive age (Giudice 2004, Falcone 2011). It is also shown to affect 50-60% of women and
adolescents who have pelvic pain (Giudice 2010). Additionally, approximately 35 to 50% of
women who experience pain and/or infertility have been found to have endometriosis
(Meuleman 2009, May 2010). The incidence of endometriosis has also been shown to depend on
race, where endometriosis incidence in African populations is roughly 27% and in South
American populations at approximately 55% (Deguara 2012). According to the National Council
of Women's Health, all of this translates into approximately 70 million women and adolescents
worldwide who have endometriosis (Carvalho 2012).
Some studies have suggested potential risk factors for endometriosis. For example, it has
been suggested that short menstrual cycles, early menarche, nulliparity, low birth weight
(Falcone 2011), late menopause, or obesity (Missmer 2004) are associated with increased risk of
endometriosis. These risk factors have been thought to be associated with prolonged endogenous
estrogen exposure as the reason for the increased chance of having endometriosis (Missmer
2004).
Other studies have also suggested a hereditary component in endometriosis risk. It has
been observed that first-degree relatives of women who have severe endometriosis are seven to
ten times more likely to have endometriosis than women who are relatives of unaffected women
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(Simpson 1980, Malinak 1980). Another study reported that a genetic predisposition of having
endometriosis is seen in approximately 15% of endometriosis cases (Okeke 2011).

Stages and Types of Endometriosis
Because endometriosis is complex to diagnose and treat, it is important to develop a good
staging system, not only to create a common language, but also to enable diagnosis specificity,
standardize comparisons, as well as to facilitate application of research findings (Okeke 2011).
The commonly used staging for endometriosis is based on the American Society for
Reproductive Medicine scoring system, which differentiates stages of endometriosis based on
implant location, appearance, invasion depth of the lesions, adhesion, and severity of the disease
(Giudice 2010). These stages include minimal disease (stage I), mild disease (stage II), moderate
disease (stage III), and severe disease (stage IV) (Falcone 2011). The basic characteristics of
each stage are briefly illustrated in Figure 4.2.
Endometriosis stage I is typically given scores between 1 to 5 points and is defined by the
presence of small spots of endometriosis without the presence of clinical symptoms (Okeke
2011). Stage II has scores between 6 to 15 points and is typically defined by the presence of
scattered fresh superficial lesions without scarring or adhesion (Okeke 2011). Stage III is scored
between 16 to 40 points and is characterized by ovary involvement with some scarring and
retraction as well as endometriomas no bigger than 2 cm (Okeke 2011). Stage IV has a score of
greater than 40, and is characterized by ovary involvement with endometriomas larger than 2 cm,
dense peritubal and periovarian adhesions that restrict mobility, thickened ligaments, as well as
bowel and urinary tract involvement (Okeke 2011).

122

Figure 4.2 Endometriosis stages (Taken from Hamod 2013).
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Although there are benefits in having a good staging system for endometriosis, some
researchers have suggested some disadvantages of the current staging system. One disadvantage
of the currently used scoring system is that these assigned stages may not necessarily be
adequate to predict progression or regression of the disease (McDonough 2001). Another
disadvantage of staging is that although it is helpful in disease burden and management
determination, these stages do not necessarily show any correlation with pain severity nor are
they able to predict clinical response to pain and/or infertility treatments (Revised American
Society for Reproductive Medicine (1996).
As seen in the outlined stages of endometriosis, it is a complex disease with different
types and stages that present with varying symptom severity. Additionally, because
endometriosis represents a significant health concern, it is therefore very important to gain a
better understanding of its pathogenesis as well as pathophysiology in order to better understand
possible preventative measures, develop more sensitive diagnostic assays, as well as effective
treatment options (Burney 2012).

Some Theories of Endometriosis Pathogenesis
Over the years several theories of endometriosis pathogenesis have been proposed.
Current theories attempt to explain the occurrence of all types of endometriosis. Some of the
main endometriosis pathogenesis theories are outlined in Figure 4.3 below.
In the Mullerian rest theory, it is proposed that under certain stimulus, embryonic cell
rests from Mullerian origins can differentiate into a functioning endometrium (Maruyama 2012).
Previous studies have shown rare occasions where patients with no menstrual endometrium such
as males have histologically confirmed endometriotic tissue (Schrodt 1980). Thus, this Mullerian
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Figure 4.3 Theories regarding the pathogenesis of endometriosis (Taken from Burney 2012).
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rest theory is particularly useful in describing these rare occurrences of endometriosis in men
because embryonic cell rests of Mullerian origins have been found to be present in both females
as well as males (Oliker 1971).
The coelomic metaplasia theory is based on the idea that currently unidentified cells,
capable of differentiating into endometrium cells, may be present within ovary and pelvic
peritoneum mesothelial cell linings (Seli 2003). This theory is promising because it can explain
endometriosis implants in many of the currently observable implantation sites (Oliveira 2012).
In the lymphatic and hematogenous theory it is proposed that endometriosis may be a
result of lymphatic distribution of endometrial cells or tissue throughout the body (Maruyama
2012). One observation that supports this theory is the observation of endometriosis in lymph
nodes in some cases of the disease (Javert 1952). This theory of endometriosis pathogenesis has
some value because it accounts for certain endometriosis cases where implants were found in
distant or unusual locations such as the lungs, lymph nodes, or brain (Maruyama 2012).

Retrograde Menstruation Theory of Endometriosis Pathogenesis
The retrograde menstruation theory was first proposed over eighty years ago and it states
that endometriotic lesions may be caused by implantation of refluxed endometrial tissue on
pelvic organs or peritoneal surfaces due to retrograde menstruation through the fallopian tubes
(Sampson 1927, Oral 1997). In his original observation when operating on women during
menstruation, Sampson noticed that peritoneal lesions were bleeding in the same manner as what
is observed in the eutopic endometrium, which proved to him that these tissues outside of the
uterus were of endometrial origin (Sampson 1927). Additionally, it has been suggested that

126
women who have endometriosis have a higher rate of retrograde menstrual flow and abnormal
myometrial contraction (Oliveira 2012).
There are many promising findings that support this theory and have made this a highly
accepted endometriosis pathogenesis theory. Some supportive findings include the fact that
menstrual blood has been shown to contain viable endometrial cells, the observation that shed
endometrial cells were able to implant and proliferate in vivo, and the universality of retrograde
menstruation which is shown to be present in 90% of women (Maruyama 2012).
However, despite promising evidence that support this theory, several shortcomings are
associated with this theory. For instance, there hasn't been any in vivo documentation of critical
pathogenesis events such as the initial attachment, proliferation, and invasion of implants on a
microscopic level (Redwine 2002). Another drawback of this theory is the observation that
although most women have retrograde menstruation, only a small fraction of these women
develop endometriosis (Giudice 2010). This observation has led to the idea that perhaps there are
underlying features, either hereditary or acquired, in women who develop endometriosis that
increases the likelihood of implantation to occur, such as certain properties of the endometrium
or defective immune clearance (Burney 2012).
One possible cause of this phenomenon involves deficiency in immune clearance. Under
normal conditions, refluxed endometrial tissue is usually cleared from the peritoneum by the
woman's immune system (Burney, 2012). However, deficiency in this clearing mechanism can
possibly lead to an increased predisposition of endometrial cell implantation and growth (Burney
2012, Dmowski 1981). Thus, it has been proposed that the development of endometriosis may be
a result of endometrial cells that are inherently resistant to immune-mediated clearance and
apoptosis, which acquire the ability to establish implants (Braun 1998).
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Stem Cell Theory of Endometriosis Pathogenesis
One of the more recent theories of endometriosis pathogenesis that has been proposed is
the stem cell theory. In the stem cell theory, it is suggested that endometrial stem/progenitor cells
are responsible for endometriosis when these cells are present ectopically (Maruyama 2012).
Stem cells are defined as cells that are able to self-renew or produce daughter cells that are
identical to the mother cell, as well as differentiate into different kinds of specialized cells
(Oliveira 2012). In the body, stem cells play an important role in regenerating dying or damaged
cells and tissue, and are therefore important contributors to structural and functional maintenance
of organs and tissues (Maruyama 2012).
Although stem cells are highly present in the embryonic development stage, these cells
are also found to be present in certain adult tissues (Gargett 2004). Stem cells are typically found
in niches, which are microenvironments that allow for the maintenance of tissue homeostasis,
self-renewal, proliferation, differentiation, as well as cell apoptosis (Oliviera 2012). Recent
studies have suggested the presence of stem cells in several tissue types or organs such as bone
marrow, breast, prostate, brain, liver, as well as the endometrium (Gargett 2004). The presence
of stem or progenitor cells in the endometrium is very plausible due to the regenerative nature of
endometrial tissue following hormonal signals as it goes through the monthly menstrual cycle
(Oliveira 2012).
Recent studies have suggested that these endometrial stem/progenitor cells may be bone
marrow derived cells. One murine model bone marrow transplantation experiment showed that
endometrial cells can originate from bone marrow derived cells, which suggested that nonuterine stem cells contributed to endometrial tissue regeneration (Du 2007). In that experiment,
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the researchers also observed that bone marrow derived cells were present in the eutopic and
ectopic endometrium, which further corroborates the idea that these bone marrow derived cells
may be involved not only in endometrial homeostasis maintenance but also in endometriosis
generation (Du 2007).
In cases of endometriosis, these endometrial stem/progenitor cells are thought to be
transported via various routes including retrograde menstruation, lymphatic dissemination, direct
migration and invasion, or a combination of these mechanisms (Maruyama 2012). Thus, the stem
cell theory appears to complement many of the present endometriosis pathogenesis theories.
For instance, in support of the retrograde menstruation theory, it is proposed that
endometrial "stem or progenitor cells" rather than endometrial "tissues" are thought to implant
and cause the formation of endometriotic lesions (Maruyama 2012). Additionally, it has also
been proposed that stem or progenitor cells can only function in the presence of an appropriate
stem cell niche, and that the presence of a suitable stem cell niche rarely coincides with an initial
implantation event (Maruyama 2012). Thus, the stem cell theory also provides a possible
explanation of why not all women who have retrograde menstruation also have endometriosis.
The stem cell theory may also possibly explain the lymphatic and hematogenous
dissemination theory because the bone-marrow is thought to be the source of these endometrial
stem or progenitor cells (Maruyama 2012). Thus, the stem cell theory can also be used to explain
endometrial implants in unusual or distant sites as well.
In the metaplasia theory, it is proposed that unidentified precursor cells in the
mesothelium or Mullerian rests are able to differentiate into endometrial cells when subjected to
specific stimuli (Seli 2003). Thus, evidence of the stem cell theory may also support the
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metaplasia theory, where these unidentified precursor cells could possibly be stem/progenitor
cells.
Despite the promise of this stem cell theory of endometriosis pathogenesis that supports
many of the other previously proposed theories, there is still no direct evidence that has been
reported for the role of these endometrial stem or progenitor cells in endometriosis pathogenesis
(Maruyama 2012). Therefore, further research on this topic is of great interest at present.
Further, regardless of the various theories that have been proposed to explain the
pathogenesis of endometriosis, none of these theories was able to fully explain and provide
detailed evidence of the pathogenesis of all the types of endometriosis known in the field. This
phenomenon may very well be due to the possibility that endometriosis is a multifactorial disease
that may involve multiple pathway involvement for its pathogenesis.

Treatments/Management
Several studies have proposed strategies to prevent the development of endometriosis.
For instance, fruits, green vegetables and long chain fatty acid consumption have been associated
with a decreased risk of endometriosis (Missmer 2004). Other studies suggest the benefits of
using oral contraceptives as well as exercise as a means to reduce the risk of endometriosis
(Simpson 2002). It has also been suggested that frequent child bearing reduces the risk of
contracting endometriosis as well (Brosens 2011).
In terms of treatment options, endometriosis pain is often treated through
pharmacological therapy, which often includes oral contraceptives. The reasoning behind the use
of oral contraceptives for this purpose is to minimize inflammation, suppress ovarian hormone
production associated with the menstrual cycle, as well as to reduce or eliminate menstruation
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(Guidice 2010). Although this type of pharmacological therapy has shown some ability to reduce
pain, this effect is not permanent, as seen in the recurrence of pain in the majority of patients
when medication was stopped (Fritzer 2012).
In cases of severe endometriosis as well as the presentation of other symptoms that can
not be treated with pharmacological therapy only, such as endometrial lesions on the digestive or
urinary tract, surgery is often the only approach to treatment (Chapron 2011). Two types of
surgical interventions can be performed, radical and conservative. Radical surgery is chosen
when patients no longer desire fertility, as the surgery involves a hysterectomy with the removal
of visible disease (Okeke 2011). Alternatively, conservative surgical therapy is used to restore
normal pelvic anatomy as well as remove visible endometriosis implants (Okeke 2011).
In using surgery for endometriosis treatment, it is very important to remove all lesions
that may have an appearance of endometriosis in order to maximize positive outcome of the
surgery (Howard 2011). Endometriosis surgery involves the removal of all lesions, and in some
cases has been shown to increase the rate of spontaneous pregnancy after surgery (Falcone
2011). Some of the objectives of endometriosis surgical treatment are to remove or destroy
endometrial implants, relieve symptoms, maintain or restore fertility, as well as to avoid or delay
symptom recurrence (Okeke 2011).
Although one of the ideal objectives of surgery is to possibly avoid the recurrence of
symptoms, it is often reported that over time endometriosis symptoms are likely to recur
(Falcone 2011). Symptom recurrence could be due to incomplete excision of disease at the time
of surgery, or true recurrence of disease (Falcone 2011). This recurrence has been shown to be
progressive over time, where it is reported to be around 15% at 1 year, 36% after 5 years, and
approximately 50% at 7 years after surgery (Falcone 2011). Because of the frequent recurrence
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of endometriosis, it has been proposed that long term endometriosis treatment may require
repeated courses of surgery, pharmacological therapy or the combination of both (Guidice 2010).

Diagnosis
At present, it has been suggested that the average time between onset of symptoms and
definitive endometriosis diagnosis is between 7 to 8 years (Falcone 2011, Chapron 2011).
Additionally, many cases of endometriosis are left undiagnosed (Koninckx 2012). One reason for
this delay is the lack of awareness of the disease and limited diagnostic tests (Fritzer 2012).
Other possible reasons for the diagnosis delay is the normalization of pain by the patients, the
inability to distinguish between normal menstrual pain and disease symptoms, the discomfort of
discussing the matter with a doctor, as well as physicians' occasional doubt regarding the severity
and intensity of symptoms as described by the patients (Fritzer 2012).
Another aspect that may contribute to a misdiagnosis or diagnosis delay of endometriosis
is the fact that many of the endometriosis symptoms are non-specific and have been associated
with several different conditions (May 2010). For instance, chronic pelvic pain is associated with
a number of diseases, such as irritable bowel syndrome, painful bladder syndrome, polycystic
kidney disease, etc (Howard 2011). Additionally, because of the various possible conditions that
may contribute to the chronic pelvic pain, it is almost impossible to determine the degree of pain
that may be attributed to each condition (Howard 2011).
One of the frequently used noninvasive approaches for endometriosis diagnosis is
imaging techniques such as pelvic ultrasound. Imaging is often performed prior to surgery in
order to investigate or assess the chronic pain (Falcone 2011). The sensitivity of this approach
has been shown to be highly dependent on the type of endometriosis lesions that are present. For
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instance, ultrasound has a high sensitivity of 84 to 100% and specificity of 90 to 100% when
used to identify ovarian endometriomas (Somigliana 2010). However, despite the high sensitivity
and specificity of using ultrasonography in diagnosing endometriomas, it is not particularly
useful for detecting other types of endometriotic implants (Okeke 2011).
To date, the most effective visual diagnosis method for endometriosis is through
laparoscopic surgery, which has been considered the "gold standard" in endometriosis diagnosis
and treatment (Falcone 2011). It has also been proposed that visual diagnosis through
laparoscopy should be accompanied with biopsies for histological confirmation of disease in
order to improve predictive value, which is particularly important because of the various
presentations that endometriosis can manifest (Howard 2011, Falcone 2011). A major drawback
of surgery as a means of diagnosis is the invasiveness and expense of the procedure. Further, a
recent study observed that laparoscopy as a visual diagnostic tool has a high false positive rate
(Walter 2001, Somigliana 2010). This means that many women would have to undergo this
invasive surgery without actually having endometriosis. Therefore, many recent studies have
taken interest in noninvasive peripheral biomarkers as potential endometriosis diagnostic tools.
In order for a biomarker to be useful in endometriosis diagnosis, the main criteria that
needs to be met is the ability of the biomarker to distinguish women with endometriosis from
non-endometriotic patients who present with similar symptoms such as dysmenorrhoea, pelvic
pain, and infertility (May 2010).
Previous studies have suggested various possible chemical biomarkers for the diagnosis
of endometriosis. Some of these biomarkers include molecules such as cytokines, antibodies,
other immunological molecules, glycoproteins, hormones, as well as molecules associated with
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cell adhesion, angiogenesis, and apoptosis (May 2010). Some of the previously proposed
putative biomarkers are summarized in Figure 4.4.
Although many diagnostic markers have been proposed for endometriosis, as shown in
Figure 4.4, currently none of these markers is clinically useful for endometriosis diagnosis. It is
possible that this may be due to the likelihood that different markers will be needed for the
diagnosis of different types or stages of endometriosis (May 2010). Further, panels of biomarkers
have been shown to yield more promising diagnostic outcomes than a single marker alone (May
2010). Therefore, there is still a significant need to discover and validate more promising
noninvasive biomarkers that can be used effectively in a clinical setting. My hypothesis is that
using our previously published serum proteomics approach (Merrell 2004), we can discover
many potential diagnostic markers that distinguishes individuals with or without endometriosis.

Our Endometriosis Biomarker Discovery Study
An initial endometriosis biomarker discovery set was used to serve as a pilot study to
determine whether or not possible serum biomarker could be found for endometriosis. This
initial endometriosis sample set consisted of serum specimens from 12 non-endometriosis
controls and 12 women who have stages III or IV endometriosis. Of the 12 endometriosis cases,
7 were from patients with stage IV and 5 were from patients with stage III. The patients'
endometriosis stages were determined through laparoscopic surgery and biopsy. Serum
specimens were processed following our previously published serum proteomics approach (See
Chapters 2 and 3, and below), the spectra were inspected for differences between cases and
controls, statistical analyses were performed, and the identities of potential markers of interest
were determined.
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Figure 4.4 Summary of previously proposed peripheral endometriosis biomarkers (Taken from May 2010).
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A second endometriosis sample set was obtained following the initial sample set. This
second serum specimen set consisted of 11 non-endometriosis controls and 6 endometriosis cases
with stages I or II disease. Of the 6 endometriosis cases in this sample set, 3 were from patients
with stage I endometriosis and the other 3 were from patients with stage II disease. This second
specimen set served both as a validation set to confirm markers previously found in the initial
set, as well as a discovery set to find novel markers that might possibly diagnose earlier stages of
endometriosis. This second specimen set was subjected to the same processing and data analysis
as the initial set.

Methods
Sample Preparation
Our previously published serum proteomics approach (Merrell 2004) involved the use of
acetonitrile to remove large and highly abundant species from the complex serum mixture. A 2:1
ratio of acetonitrile to serum was used, where 200 μL of serum was mixed with 400 μL of
acetonitrile, vortexed for approximately 10 seconds, and allowed to incubate on the bench at
room temperature for 30 minutes. Upon incubation, the acetonitrile-serum mixture was
centrifuged at 14,000 rpm (IEC Micromax RF, Thermo Fisher Scientific, Waltham, MA) to
remove any large or highly abundant species that precipitated out of the solution with the
addition of acetonitrile. The pellet, containing the precipitated portion of the serum was
discarded, leaving a supernatant containing the low molecular weight portion of the serum. The
supernatant (~550 µL) was transferred to a fresh microcentrifuge tube and mixed thoroughly
with 300 µL of HPLC grade water. The mixture was placed in a vacuum centrifuge (CentriVap
Concentrator Labconco Corporation, Kansas, City, MO) and its volume reduced to ~200 µL to
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eliminate any remaining acetonitrile in the mixture. The apparent protein concentration was
determined using a Bio-Rad microtiter plate protein assay, following the manufacturer’s
instructions (Bio-Rad Laboratories, Hercules, CA) and an aliquot containing 4 µg apparent
protein was transferred from the protein-depleted mixture into a fresh microcentrifuge tube. The
aliquot was lyophilized (CentriVap Concentrator Labconco Corporation, Kansas, City, MO) to
less than 20 µL, and the volume of all the processed serum specimens were brought up to 20 µL
by adding HPLC grade water and acidified with 20 µL of 88% formic acid. The acidified
specimens were submitted to cLC-MS analysis via autosampler injection (Dionex Corporation,
Sunnyvale, CA).

cLC-MS Analysis of Protein Depleted Specimens
The cLC instrument used an LC Packings Ultimate Capillary HPLC pump system. The
injected specimens were fractionated by a capillary liquid chromatography (cLC) system which
utilized a 1 mm (16.2 μL) dry-packed microbore guard column (Upchurch Scientific, Oak
Harbor, WA) and a 15 cm x 250 μm i.d. slurry packed capillary column assembled in-house.
The media used to assemble both columns was POROS R1 reversed-phase media (Applied
Biosystems, Framingham, MA). The chromatographic separation gradient was performed using
an aqueous phase (98% HPLC grade H2O, 2% acetonitrile, 0.1% formic acid) and an organic
phase (2% H2O, 98% acetonitrile, 0.1% formic acid). Elution began with 3 min of mobile phase
containing 95% aqueous phase and 5% organic phase, followed by a linear increase to 60%
organic phase over a period of 24 min. The gradient was increased to 95% organic phase over 7
min and held at that concentration for 7 min. The gradient was then returned to 95% aqueous
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phase over 5 min and held there to re-equilibrate the column. The flow rate was 5.0 μL/min. The
runs were managed using Analyst QS® 1.1 software (Applied Biosystems, Foster City, CA).
The cLC system was interfaced with a QSTAR Pulsar I quadrupole orthogonal time-offlight mass spectrometer through an IonSpray source (Applied Biosystems) set at 4800V. All
experiments for this study were done in positive ion mode. The cLC-MS data were collected for
m/z 500 to 2500 from 5 to 55 min of the cLC elution with mass spectra obtained every 1 sec. The
elution profile of each cLC fractionated sample was reported as the total ion chromatogram
(TIC) and the results analyzed using Analyst QS® 1.1 software (Applied Biosystems, Foster
City, CA).

Comparisons of Endometriosis Cases and Non-Endometriotic Controls
The TIC for each specimen representing all the molecular ion species eluting over a
period of 55 minutes were divided into 10 two-minute segments based on serum time markers
previously described (Merrell 2008). This time division was performed to simplify the data
analysis process by analyzing two-minutes of data at a time rather than the entire 55 minutes at
once. Within each two-minute window, the spectra for endometriosis cases and nonendometriotic controls were overlaid and color-coded to distinguish the two groups. Overlaid
spectra were visually inspected and potential markers that appear to be in differing amounts
between the two specimen groups (Figure 4.5) were recorded for further analyses.
This visual inspection step yielded many potential markers that appeared to be different
between cases and controls. The intensities of potential markers found in the visual inspection
step were recorded for each of the 24 specimens in the initial specimen set. These intensities
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Figure 4.5 Example of an overlay of non-endometriosis controls and endometriosis cases.
The cases are color coded in red and the controls are in blue. This overlay represents one of the potential
endometriosis markers that appear visually different between the two specimen groups.
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were used in statistical analyses. Additionally, reference peaks were also obtained for data
normalization, and their intensities were recorded as well.

Statistical Analyses
The peak height in ion counts was used as a measure of peak abundance. The peak
heights of potential markers of interest from the initial sample set were subjected to Student's Ttest to determine statistical significance of the differences observed in the visual inspection step.
A p-value of <0.05 was considered statistically significant. Additionally, we also considered
markers with a p-value of less than 0.1 for further statistical analyses involving the development
of biomarker panels with higher specificity and sensitivity. Thus, all the markers discovered in
the initial set with a p-value of less than 0.1 were sent to a biostatistician for further statistical
analyses, including testing for batch effects, measurements of single marker area under the curve
(AUC), biomarker panel development, as well as marker frequency of occurrence in multiple
panels.
Prior to these additional statistical analyses, it was observed that more than 43% of the
markers were able to predict batch (which day the specimens were run) with an AUC of > 0.6,
which indicates that many of the markers were better predictors of batch
than of endometriosis. To overcome this, the biostatistician utilized a software ComBat (Johnson
2007) to remove the batch effect. Upon removal of batch effect, it was found that only two
markers had an AUC of greater than 0.64 in predicting the batch, as opposed to the 17 markers
observed in the initial set prior to batch removal. Thus, this adjusted data set was used for further
statistical analyses.
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Single marker AUCs were also calculated for each of the potential markers. For the
calculation of single marker AUCs, Pearson correlation, logistic regression and the receiver
operator characteristic curve analyses (Sing 2009) were performed.
A forward selection logistic regression approach was used for biomarker panel
development. In the forward selection procedure, a protein marker was added to the panel one at
a time based on whether or not it increases the combined AUC. Once addition of markers did not
increase the combined AUC, the panel was optimized. Of the many marker combinations
developed using this approach, four panels consisting of markers with known identities are
reported in detail here. Additionally, how often each marker occurred in different biomarker
panels was also determined by ranking the markers based on which markers appeared in most
panels.
For the second endometriosis sample set, which consisted of earlier stages of
endometriosis, the only statistical analysis that has currently been performed is the Student's Ttest to determine the p-value of potential markers. The T-test was performed on both markers
found in the initial later-stage endometriosis set (for validation of previously found markers), as
well as for newly discovered markers (through visual inspection of the 2nd specimen set to
determine differences between non-endometriotic controls and patients with early stage
endometriosis).

Biomarker Sequencing Using MS/MS with QSTAR Pulsar I Quadrupole Orthogonal Timeof-Flight Mass Spectrometer
MS/MS fragmentation experiments were attempted on markers with good p-values and
AUC. To do this, previously run MS spectra were inspected to find specimens that had a high
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abundance of marker of interest. A protein-depleted specimen containing as much of the protein
of interest as possible was thawed and subjected to 2 shorter initial cLC-MS runs to determine
the exact elution time of the molecule of interest, followed by the actual MS/MS fragmentation
runs using various collision energies to obtain good fragmentation coverage (as detailed in
Chapter 3 Methods section). Further, descriptions of sample injection, data correction and
analyses are also outlined in Chapter 3 Methods section. In instances when Mascot searches
didn't yield good matches for peptide markers, de novo sequencing strategies were employed.
Additionally, for lipid markers, the lipid de novo sequencing approach was used, both of which
are also described in Chapter 3 Methods section).

Peptide Sequencing Using MS/MS With LTQ-Orbitrap XLTM Hybrid Mass Spectrometer
In instances where an amino acid sequence could not be obtained using the Qstar
instrument, we also utilized an LTQ-Orbitrap XLTM for amino acid sequence determination.
Details of the MS/MS runs on the Orbitrap, data conversion and analysis are outlined in the
Methods section of Chapter 2. For our endometriosis study, only one marker of interest was
fragmented on the Orbitrap, biomarker m/z 537.3.

Results
Overview of Discovered Diagnostic Markers for Later Stages of Endometriosis
In the initial biomarker discovery set, comparing non-endometriotic controls and later
stages of endometriosis cases (stages III and IV), 23 biomarkers were found to have a p-value of
< 0.05, and a total of 39 potential biomarkers were found to have a p-value of < 0.1. Of those
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candidate markers, 9 molecules have been submitted to MS/MS analysis and the amino acid
sequence or compound structures of 6 of these have been solved and are reported here. The
others have not been identified due to a lack of additional specimens containing a sufficient
amount of the markers of interest.
Of the 6 identified molecules, five are peptides, and the sixth is a phosphocholine
molecule. Table 4.2 outlines the detailed identification of the 6 known biomarkers. Additional
sequencing experiments for the many other endometriosis biomarkers are pending additional
specimen.

Identified Later Stage Endometriosis Peptide Biomarkers
Of the 5 identified peptides, 2 of those identifications were obtained through a Mascot
search, peptides m/z 537.3 and 1015.4 (Figures 4.6 and 4.7). The Student's T-test calculations
revealed that peptide m/z 537.3, a fragment of HERV-W_7q21.2 provirus ancestral envelope
polyprotein, was significantly higher in cases of endometriosis, with a p-value of 0.0034 and a
single marker AUC of 0.792. The peptide m/z 1015.4 was found to be higher in nonendometriotic controls with a p-value of 0.08 and an AUC of 0.75.
The other three peptide biomarkers identified, peptides m/z 698.8, 1220.5, and 655.3,
required de novo peptide sequencing. Peptide m/z 698.8 (Figure 4.8), a fragment of β fibrinogen, was found to be higher in non-endometriosis controls with a p-value of 0.07 and a
single marker AUC of 0.604. The peptide m/z 1220.5 (Figure 4.9), a different fragment of βfibrinogen, was higher in non-endometriosis controls with a p-value of 0.069 and a single marker
AUC of 0.597. Peptide m/z 655.3 (Figure 4.10), a fragment of fibrinopeptide A, was also found
to be higher in controls with a p-value of 0.096 and a single marker AUC of 0.486.
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Table 4.2 Amino Acid Sequence or Chemical Structure for Endometriosis Candidate Biomarkers
m/z
537.3

charge

MW

sequence/structure
thtrlvslf

parent protein/compound
HERV-W_7q21.2 provirus ancestral
envelope polyprotein

2

1072.6

1015.4

1

1014.4

dneegffsa

Fibrinogen β-chain

698.8

2

1395.6

apvndneegffsa

β -fibrinogen

1220.5

1

1219.5

pyro-egvndneegff (-H20)

β -fibrinogen

655.3

2

1308.6

dsgegdflaegggv

568.3

1

567.3

Fibrinopeptide A
1-(4Z, 7Z, 10Z, 13Z, 16Z, 19Zdocosahexaenoyl)-sn-glycero-3phosphocholine

PC (22:6)
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Figure 4.6 Mascot search match for peptide m/z 537.3 indicating that this peptide is a fragment of HERVW_7q21.2 provirus ancestral env polyprotein.
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Figure 4.7 Mascot search match for peptide m/z 1015.4 indicating that this peptide is a fragment of fibrinogen
β-chain.
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Figure 4.8 MS/MS fragmentation spectra for peptide m/z 698.8 with the amino acid sequence obtained from
de novo sequencing labeled, indicating that this peptide is a fragment of β-fibrinogen.
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Figure 4.9 MS/MS fragmentation spectra for peptide m/z 1220.5 with the amino acid sequence obtained from
de novo sequencing labeled, indicating that this peptide is a fragment of β-fibrinogen.
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Figure 4.10 MS/MS fragmentation spectra for peptide m/z 655.3 with the amino acid sequence obtained from
de novo sequencing labeled, indicating that this peptide is a fragment of fibrinopeptide A.
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Identified later stage endometriosis lipid biomarkers
The last identified marker was a phosphocholine molecule, marker m/z 568.3 (Figure
4.11). This marker was identified as lyso-PC (22:6), and was found to be higher in endometriosis
cases with a p-value of 0.07 and a single marker AUC of 0.799.

Validation of Markers from Later Stages of Endometriosis in Early Stages of
Endometriosis
The second specimen set which consisted of sera from 11 non-endometriosis controls and
6 women with endometriosis stages I and II specimens was used as both a validation set to
confirm markers previously found in the initial set, as well as a discovery set to find novel
markers that can diagnose these earlier stages of endometriosis.
As a validation set, we performed statistical analyses on candidate markers from the
initial set to see if they are still statistically significant in this second set. Of the 39 markers
found in the initial set, 7 of them remained statistically significant (p-value < 0.1) in this second
set. Table 4.3 summarizes the validation results.
As can be seen in Table 4.3, three of our identified markers (peptides m/z 655.3, 1015.4,
and 698.8) were part of the 7 markers validated in the second set. It is also important to note that
this second set may not have been ideal for validating markers from the original set because the
endometriosis cases in both sets differ by disease stages (the initial set consisted of endometriosis
stages III and IV, while the 2nd set consisted of endometriosis stages I and II). However,
regardless of the stage differences, some of the markers appeared to be significant in both late as
well as early stages of endometriosis.
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Figure 4.11 MS/MS fragmentation spectra of molecule m/z 568.3 with the predicted fragments labeled.
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Table 4.3 Validation of Endometriosis Candidate Markers in a Second Specimen Set
m/z
1st set (p-value)
2nd set (p-value)
655.3

0.096

0.087

821.3

0.09

0.08

1015.4

0.08

0.03

698.8

0.07

0.09

648.4

0.07

0.09

692.4

0.03

0.05

808.6

0.098

0.078
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Biomarker Discovery for the Early Stages of Endometriosis
As a biomarker discovery set, we followed the same procedure as used in the initial set.
In this set of earlier stages of endometriosis, we observed 70 molecules with p-value <0.05, and
101 molecules with p-value <0.1 as distinguishing cases from control specimens. MS/MS
analyses of statistically significant markers are currently on hold due to lack of additional
specimen containing sufficient amounts of markers of interest.

Biomarker Panels for Later Stages of Endometriosis
As seen in the data mentioned above, no single marker from our initial analysis of later
stage endometriosis gave an AUC of > 0.8. Thus, further statistical analyses were conducted to
develop panels of biomarkers that together could provide an AUC of > 0.8 for the detection of
endometriosis. Several panels (Table 4.4) were obtained from these statistical analyses, and four
of these panels are reported in detail here (bold font in Table 4.4), which consisted of molecular
biomarkers with known sequences or compound identity.
Our best biomarker panel consisted of just two markers m/z 537.3 and 1220.5 (Figure
4.12). This biomarker panel yielded an AUC of 0.947, with a sensitivity of 83% and a specificity
of 100%.
The second best endometriosis biomarker panel consisted of markers m/z 698.8 and
537.3 (Figure 4.13). In this biomarker panel, an AUC of 0.896 was achieved. Additionally, the
sensitivity of this panel in endometriosis diagnosis was 82%, with a specificity of 100%.
The third biomarker panel was comprised of markers 568.36 and 698.8 (Figure 4.14).
This panel gave an AUC of 0.854 and provided a sensitivity of 90% at a specificity of 80% for
endometriosis diagnosis.
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Table 4.4 Several Good Candidate Biomarker Combination Models for Later Endometriosis Diagnosis
Markers
AUC
537.3, 1220.5
0.947
568.36, 698.8, 821.3
0.942
537.3, 530.4
0.903
537.3, 698.8
0.896
537.3, 692.4
0.875
568.8, 698.8
0.854
537.3, 1015.4
0.847
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Figure 4.12 ROC plot and predicted probability for the biomarker panel consisting of marker m/z 537.3 and
1220.5.
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Figure 4.13 ROC plot and predicted probability for the biomarker panel consisting of marker m/z 698.8 and
537.3.
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Figure 4.14 ROC plot and predicted probability for the biomarker panel consisting of marker m/z 468.36 and
698.8.
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The last marker panel is comprised of markers m/z 1015.4 and 537.3 (Figure 4.15). The
AUC of this panel was 0.847, with a sensitivity of 77% and a specificity of 90% for diagnosing
later stage endometriosis.
Additionally, our markers with known identities were among the most frequent
occurrences, where marker m/z 537.3 occurred in 85% of the models, markers m/z 655.3 and
1015.4 individually in 38% of the models, m/z 1220.5 in 15% of the models, m/z 568.36 in 13%
of the models, and marker m/z 698.8 in 10% of the models.

Discussion
Our hypothesis that our serum proteomics approach could find and identify biomarkers
diagnosing endometriosis appears to be validated. Of the 39 potential late stage endometriosis
biomarkers, we performed MS/MS fragmentation studies on 9 molecules and were able to
determine marker identities for 6 of these markers. None of these markers individually had an
AUC of > 0.8. Panels of biomarkers were developed, many of which yielded an AUC of > 0.8,
and four panels comprising of markers with known identities were reported in detail above. Thus
the development of biomarker panels clearly improved the diagnosis capability of these markers.
In a second specimen set, we were able to validate some of our markers, while others
were not validated. This is perhaps in part due to the endometriosis stage differences in the
specimens used. Also, the number of specimens were few, especially for cases. In addition to
marker validation, this second specimen set (early stage endometriosis comparison to nonendometriotic controls) was also used to discover novel biomarkers for the diagnosis of
endometriosis. This discovery yielded many potential markers that are currently awaiting further
statistical analyses and biomarker identification experiments.
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Figure 4.15 ROC plot and predicted probability for the biomarker panel consisting of marker m/z 1015.4 and
537.3.
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Our best single endometriosis marker for later stage diagnosis was peptide m/z 537.3,
with a p-value of 0.0034 and a single marker area under the curve of 0.792. Additionally, the
frequency of this marker occurring in all panels was 85%. Through MS/MS analysis, this marker
was found to be a fragment of HERV-W_7q21.2 provirus ancestral envelope polyprotein.
HERVs are retroviral elements that were incorporated into the human genome millions of years
ago and have become fixed in the human genome (Oppelt 2009). There are several classes of
HERVs, one of which is HERV-W whose envelope gene (env) is known to code for syncytin
which has been shown to play an important role in human placenta morphogenesis (Oppelt
2009).
The idea of an association between HERV-W and endometriosis was first considered
based on a previously published study showing the expression of endogenous retroviruses in
hormone-dependent and hormone-producing organs (Schiff 1991). In response to this
observation, it has been proposed that perhaps the development of endometriosis may be
influenced by endogenous retroviruses, as it is a hormone-associated disease (Oppelt 2009).
Syncytin, a protein product of the HERV-W gene, was previously found to be seven
times higher in concentration in tissue from endometriosis patients than in normal endometrium
(Oppelt 2009). Therefore, it has been suggested that perhaps in the retrograde menstruation
theory, endometrial cells with an increased HERV-W expression that reach various implantation
sites have a higher likelihood of implanting (Oppelt 2009). Undoubtedly, additional studies are
still needed to confirm these findings.
From this summary, we can conclude that there are several potential endometriosis
biomarkers, both for later as well as early stage endometriosis diagnosis that were observed
following this approach. Validation of these markers through additional analysis of other sets of
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specimens would be important to confirm our initial findings. Further, these additional
specimens will also be of great value in determining the sequence identity or chemical structures
of several additional endometriosis biomarkers.
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5. Chapter 5 - Concluding Remarks
Summary of Current Research Accomplishments
Summary of Our Tissue Proteomics Research
We have developed a tissue proteomics approach for the analysis of the low molecular
weight/low abundance species in tissue. This approach involved tissue homogenization, followed
by acetonitrile precipitation to remove the large and highly abundant species in tissue. In the
development of this approach, two main criteria were tested, the ability to observe tissue specific
differences when various tissue types were subjected to this approach, and the ability to obtain
fairly reproducible results. In testing this approach, we have indeed confirmed the value of this
tissue proteomics approach in observing tissue-specific differences in the low molecular
weight/low abundance proteome of tissue. Furthermore, reproducibility was tested across several
scenarios and multiple data normalization approaches were attempted, which lead us to the
conclusion that the variability observed in this tissue proteomics approach is within the range of
variability seen in several other proteomics approaches currently being implemented in the field.
Taken together, this approach should provide a potential means for future studies where tissue
differences are of interest, such as in disease studies.

Summary of Our PE Research
Candidate PE markers have been previously determined from serum specimens of
preeclamptic and non-preeclamptic pregnancies at 12-14 weeks gestation. These candidate
markers were previously found to provide statistical significance between disease cases and nonpreeclamptic controls and were further analyzed to determine the amino acid sequence identities

162
or chemical composition. These markers were also submitted to further statistical analyses which
yielded biomarker combinations or panels with a higher sensitivity and specificity in PE
prediction than what was obtained from any single marker. Of the many markers that showed
statistical significance in distinguishing cases from controls, MS/MS amino acid sequence or
chemical compound determination was successfully performed on 8 markers. Five of these
markers were peptides, while the other 3 were found to be glycerophosphocholine compounds.
Identification of the peptide markers was conducted following a previously published strategy
(Merrell 2009), while the lipid markers were identified using a combination of strategies that we
have developed over several months. Biomarker panels were also developed using the identified
candidate PE markers. Of the many panels that were developed, three are reported here, which
demonstrated an AUC of greater than 0.8 which is the generally accepted AUC value in a
clinical setting.

Summary of Our Endometriosis Research
In our initial endometriosis pilot study, serum specimens from non-endometriotic patients
were compared to specimens from people with later stages of endometriosis (stages III and IV).
This initial study yielded many potential diagnostic markers that showed statistically significant
differences between cases and controls. Following this, several of the promising markers were
also subjected to MS/MS fragmentation analyses for sequence or chemical determination. Of the
many promising markers, we were able to obtain sequence or chemical compound information
for six markers, five of which were peptides and the sixth a lyso-glycerophosphocholine
molecule. Further statistical analyses were also conducted for single marker AUC determination
as well as biomarker panel development. Of the many biomarker panels that were developed,
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four are reported here, which consisted of biochemical molecules of known identities based on
our MS/MS fragmentation data.
Additionally, we also obtained a second set of specimens consisting of serum from nonendometriotic individuals and individuals with earlier stages of endometriosis (stages I and II).
This second specimen set served both as a validation of the initially discovered biomarkers as
well as a fresh discovery set to determine potential markers for early stage endometriosis. As a
validation set, we looked for markers from the later stages of endometriosis in this second set of
earlier stages and performed statistical analyses to determine whether or not these markers are
still valid in the second set of specimens. We found that while not all of the markers were
validated, a handful of them were validated in this second set. As a discovery set we found many
potential markers with statistical significance in differentiating controls from early endometriosis
cases.

Limitations of Current Research
Limitations of Our Tissue Proteomics Research
Although we concluded that the tissue proteomics approach we have developed has
variability that is within the range of several other currently used proteomics approaches, this
method can be improved upon. For instance, our data suggested that the variability observed in
this approach is likely due to biological variability. Biological variability such as age, gender,
feeding, immune status, breed, sample collection timing, etc, were not controlled for when we
initially obtained the tissue specimens from the abattoir. Additionally, while a certain amount of
effort was made to be consistent in tissue dissection, there is possible variability in the exact
cellular composition of the tissue slices being homogenized that may have also contributed to the
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variability observed. It would be useful for future studies to involve additional efforts to control
for some of these variables. Additionally, this tissue proteomics approach was only attempted on
sheep organs (heart, lungs, liver, kidney, spleen) for the purpose of method development.
Therefore, it may also be of value to test this approach on different tissue types as well as
different organisms as well.

Limitations of Our PE Research
Our previous PE biomarker discovery study yielded several promising biomarkers as well
as biomarker panels consisting of markers with known identity that have good disease predictive
value. However, there are several issues that still need to be addressed for the benefit of not only
this study but also future studies in our lab. For instance, prior to the commencement of our PE
biomarker identification project, it has always been assumed that our serum proteomics approach
yielded protein-depleted serum that mainly consisted of low molecular weight and low
abundance peptides. While this may still be true, this PE biomarker identification project made
us aware of the presence of compound-types other than peptides that are also present in our
protein-depleted serum specimens. An additional compound type we discovered, and
coincidentally were able to identify is glycerophosphocholines or phosphotidylcholines.
However, there were still several potential compound types present in our protein depleted serum
specimens whose identities are yet to be determined. As such, some decisions for future studies
need to be made regarding whether or not the method needs to be adjusted to exclusively isolate
certain compound-types to simplify data analysis.
Additionally, there are still many of our potential markers that have yet to be fragmented
to determine their sequence or chemical identity. Part of the limitation is due to a lack of
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carefully collected serum specimens containing a good amount of the markers of interest to allow
fragmentation.

Limitations of Our Endometriosis Research
Although we were able to obtain many potential markers, identify several of them, and
were able to develop several potential panels for the diagnosis of later stage endometriosis, there
are still a number of issues to be considered in this study. Firstly, the data set that was used for
the initial study of later stage endometriosis consisted only of 24 specimens total, 12 cases and
12 controls. While this may be considered sufficient for a pilot study, a larger data set would be
desirable to further study the disease. Additionally, the second data set for earlier stage
endometriosis biomarker discovery was also small, consisting of 11 non-endometriosis controls
and 6 endometriosis cases. As a validation set, a larger sample set would have been desirable to
use but was not available. In addition to the sample set size, the second set of earlier stage
endometriosis was not the most ideal specimen set for biomarker validation due to endometriosis
stage differences where the first and second specimen set represented different stages of
endometriosis and therefore not all the biomarkers were validated.

Future Research Objectives
Future Research Objectives for the Tissue Proteomics Project
One study that can be done to improve reproducibility is to introduce a heavy isotope
spike of one of the peptides of interest into the specimens as a means of data normalization.
Another future study that may be conducted is to attempt this tissue proteomics approach on
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other tissue types or other organisms to validate the use of this approach in other tissues. In fact,
studies are currently underway to apply this tissue proteomics approach in the study of normal
and preeclamptic placenta. The ultimate goal of the development of this tissue proteomics
approach is to eventually develop a method to study tissue-specific diseases. However, in order
to do so, further studies should be conducted to improve upon our current research findings.
Additionally, in future studies it will be important to control for biological variables, such as age,
gender, immune state, specimen processing and storage, etc. While these were hard to control at
an abattoir, most of these can be controlled or accounted for in the laboratory or clinical setting
as part of disease studies.

Future Research Objectives for the PE Project
Several future studies can be proposed for the PE project. One important project involves
the validation of the original markers obtained from the initial biomarker discovery study. In
fact, these validations are currently underway, where the intensities of our original markers are
measured in a separate set of samples of pregnancy serum drawn at 12 to 14 weeks gestational
age and determinations are made regarding which of the original markers still remain statistically
significant between non-preeclamptic controls and PE cases.
It should be noted that many multi-marker panels, where the identity of one or more
marker was unknown gave even better sensitivities and specificities. Therefore, it is also of
interest to chemically identify more of these PE markers. This effort not only involves
conducting additional MS/MS fragmentation of markers that have never been fragmented or
successfully sequenced previously, but also involves developing new MS/MS data analyses
approaches to determine the chemical identity of markers that appear to be non-peptidic in

167
nature. Clearly, knowing the identity of these promising biomarkers will be a high priority for
future research but await clinical studies to provide more specimens.
One adjustment that could be made in our sample processing approach is to use multiple
sample processing methods that allow us to look at the compound subsets (peptidome,
metabolome, lipidome, etc) in the protein-depleted serum separately. This allows for the
identification of various compound types that could provide meaningful disease information that
could complement each other without having one subset interfere with the analysis of another
subset. In order to do this, however, additional MS/MS fragmentation and data analyses
approaches will also be needed because it is currently beyond our MS/MS data analysis limits to
effectively identify non-peptidic and non-glycerophosphocholine compounds.

Future Research Objectives for the Endometriosis Project
One future study for the endometriosis project is to perform validation of the later stage
endometriosis markers on a separate sample set of the same stage of endometriosis in a blinded
manner. Although some validation has already been done for these markers in a sample set from
different endometriosis stages, it is likely that better validation can be achieved when using the
same endometriosis stages as in the original sample set. Also, with regard to validation, it will
also be beneficial to perform validation studies on the markers from the early stage
endometriosis discovery as well. Larger numbers of specimens is also highly desirable.
As in the PE study, many multi-marker panels containing markers with unknown
identities gave even better sensitivities and specificities. Therefore, in addition to biomarker
validations, it will also be of value to perform additional MS/MS experiments to determine
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sequence or chemical identity of other endometriosis markers. In order to do so, additional
specimens must be obtained that contains a good amount of our markers of interest.
Lastly, if additional specimens are available to represent the four different endometriosis
stages, it would be of interest to perform stage to stage comparison studies. For example, a study
can be conducted to observe disease progression where perhaps certain markers may gradually
increase in quantity as the disease severity increases. Another stage comparison study that should
be attempted is to determine blood serum markers that are unique to each stage which can
eventually be used for definitive diagnosis of which endometriosis stage the patient may have.
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